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Psoriasis is a skin disease originally thought to be a primary keratinocyte 
differentiation and maturation disease.  Several T cell targeted theraputics were found to 
reverse disease, and thus subsequent research has focussed on the adaptive immune 
system, particularly effector CD8
+
 T cells infiltrating the epidermis.  Recent studies, 
however, show that inhibitors of tumor necrosis factor (TNF) are also effective 
therapeutics.  Activated dendritic cells (DCs) produce large ammounts of TNF which acts 
in an autocrine loop to increase DC maturation.  Thus, TNF inhibitors may inhibit DC 
maturation and downstream T cell activation.  This thesis elucidates DC subsets present 
in normal human skin and psoriasis lesional skin, and the mechanisms by which psoriatic 
inflammatory DCs activate Th17 T cells and downstream mediators to maintainan 
psoriatic cutanous inflammation. 
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 cells is similar to normal, however, there was a 
30-fold increase in “inflammatory“ CD11c
+
 cells that did not express either marker.  
Most BDCA-1
+
 cells expressed maturation markers CD205 and DC-LAMP, while most 
BDCA-1
-
 inflammatory cells expressed CD209 immature DC/ macrophage marker.  
Some myeloid cells expressed TNF and inducible nitric oxide synthase (iNOS).  
Treatment of psoriasis patients with the TNF neutralizing antibody etanercept not 
only inhibited dendritic cells as expected, but also had inhibitory effects on a newly 
appreciated type of T cell – Th17 cells.  Etanercept reduced inflammatory DC products 
that drive Th17 cell proliferation (IL-23) as well as Th17 products and downsteram 
effector mollecules (IL-17, IL-22, CCL20, and DEFB4).  In contrast, Th1 cellular 
products and effector molecules (IFN , LTA-1, and MX-1) were reduced late in disease 
resolution.  Using affymetrix gene array we characterized a global set of 4 gene clusters 
modulated temporally over the course of etanercept treatment.  TNF and IL-17 pathway 
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Psoriasis is a skin disease originally thought to be a primary keratinocyte 
differentiation and maturation disease.  Several T cell targeted theraputics were found to 
reverse disease, and thus subsequent research has focussed on the adaptive immune 
system, particularly effector CD8+ T cells infiltrating the epidermis.  Recent studies, 
however, show that inhibitors of tumor necrosis factor (TNF) are also effective 
therapeutics.  Activated dendritic cells (DCs) produce large ammounts of TNF which acts 
in an autocrine loop to increase DC maturation.  Thus, TNF inhibitors may inhibit DC 
maturation and downstream T cell activation.  This thesis elucidates DC subsets present 
in normal human skin and psoriasis lesional skin, and the mechanisms by which psoriatic 
inflammatory DCs activate Th17 T cells and downstream mediators to maintainan 
psoriatic cutanous inflammation. 
In normal blood, ther exists 3 non-overlapping subsets of myeloid dendritic all of 
which are Lin-CD11c+HLA-DR+ and either BDCA-1+ (24 ± 2%), CD16+ (70 ± 4%), or 
BDCA-3+ (5 ± 1%), in order of immunostimulatory capacity.  Only two myloid dendritic 
cell populations exist in normal human dermis: Lin-CD11c+HLA-DR+CD16+ and either 
BDCA-1+ (≈ 90%) or BDCA-3+ (≈ 10%).  In situ double-label immunofluorescence 
showed that approximately 10-15% of CD11c+ dermal cells cluster together in lymphoid-
like structures and are BDCA-1+CD205+DC-LAMP+.  Upon emigration from the dermis, 
90-95% of BDCA-1+ cells expressed these mature antigens, stimulated allogeneic T cells, 
and increased immunostimulatory capacity after the addition of  TNF, PGE2, IL-1β, and 
 2 
IL-6.  Functional studies were not performed on BDCA-3+ cells because of limited cell 
numbers.  In normal dermis there also exists a large population of FXIIIA+CD163+ 
macrophages that are not immunostimulatory and phagocytose large particles.   
As in normal blood, psoriasis patient blood contained 3 non-overlapping subsets 
of myeloid DCs (BDCA-1+, CD16+, or BDCA-3+).  In psoriatic skin the frequency and 
distribution of BDCA-1+ and BDCA-3+ cells is similar to normal, however, there was a 
30-fold increase in “inflammatory“ CD11c+ cells that did not express either marker.  
Most BDCA-1+ cells expressed maturation markers CD205 and DC-LAMP, while most 
BDCA-1- inflammatory cells expressed CD209 immature DC/ macrophage marker.  
Some myeloid cells expressed TNF and inducible nitric oxide synthase (iNOS).  
Treatment of psoriasis patients with the TNF neutralizing antibody etanercept not 
only inhibited dendritic cells as expected, but also had inhibitory effects on a newly 
appreciated type of T cell – Th17 cells.  Etanercept reduced inflammatory DC products 
that drive Th17 cell proliferation (IL-23) as well as Th17 products and downsteram 
effector mollecules (IL-17, IL-22, CCL20, and DEFB4).  In contrast, Th1 cellular 
products and effector molecules (IFNγ, LTA-1, and MX-1) were reduced late in disease 
resolution.  Using affymetrix gene array we characterized a global set of 4 gene clusters 
modulated temporally over the course of etanercept treatment.  TNF and IL-17 pathway 









Psoriasis epidemiology and phenotype 
Psoriasis vulgaris affects 2-3% of the population (Lebwohl, 2003).  Most people 
with psoriasis have a mild form of the disease that affects less than 20% of their body 
surface area, typically appearing as itchy red patches behind the ears, around the 
eyebrows or scalp, or on extensor areas (elbows, knee caps).  Approximately 5% of 
psoriatic patients have severe disease covering more than 80% of their total body surface 
area.  Affected areas are clearly demarcated, red, and scaly.  Plaques typically remain 
stationary over time (if untreated) and can appear in areas after injury such as a severe 
sunburn or trauma to the skin– a sign known as the Koebner phenomenon (Barisic-
Drusko and Rucevic, 2004).  Psoriasis has a genetic component as evidenced by 80% 
penetrance between monozygotic twins and 30% between dizigotic twins (Bowcock, 
2004; Brandrup et al., 1978; Brandrup et al., 1982).  Aproximately 20% of psoriatic 
patients also have arthritis. 
 
Psoriasis histology 
Normal epidermis has four discrete layers:  The basal layer attached to the dermis 
by hemidesmosomes, the spiny layer which gets its spiny appearance from solid 
intercellular desmosome attachments, the granular layer due to keratohyaline granules 
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forming in the keratinocytes (KCs), and the stratum corneum consisting of old granular 
cells that have lost their nuclei and form a waxy outer barrier that protects the skin from 
dehydration and mechanical damage.  Psoriasis skin is flaky, red, and itchy – all of which 
can be explained by looking at psoriatic plaque histology.  The most glaring difference 
between psoriatic and normal skin is a greatly thickened epidermis with elongated rete 
ridges extending deep into the dermis.  The thickening is a result of an increase in 
epidermal proliferative rate by 20X.  In addition, there is a reduced transit time of KCs 
migrating outward through the epidermis, from 28 days to 4 days.  This leads to nuclei 
being retained in the stratum corneum (parakaratosis) because cells have not had a chance 
to mature and differentiate.  For similar reasons, the stratum corneum in psoriatic tissue is 
abnormal because immature granular cells are not able to form strong intercellular 
connections.  In the dermis, psoriatic blood vessels are also elongated and dilated, 
surrounded by leukocytes, resulting in redness and itch (from cytokine release).  Notably, 
follicular epithelial lining is unaffected by the disease (Bowcock and Krueger, 2005). 
 
Psoriasis-like animal models 
 It should be emphasized at the outset that there is no spontaneous model of 
psoriasis in animals. However, the use of genetically engineered xenograft transplant 
mice has aided greatly in understanding some of the basic mechanisms of skin 
inflammation as they apply to psoriasis and other inflammatory diseases.  Several murine 
models of “psoriasis” are now described. 
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Constitutive p40 expressing keratinocyte model:  IL-12 and IL-23 (related 
cytokines that share a p40 subunit) stimulate T cells to differentiate and produce IFNγ 
and IL-17/IL-22, respectively. Mice were genetically engineered to constitutively express 
p40 in the skin by joining the keratin-14 promoter with the p40 gene (Kopp et al., 2001). 
Although it was expected that these mice would overproduce both IL-12 and IL-23, basal 
keratinocytes co-secrete transgenic p40 only with endogenous p19 to constitutively 
produce IL-23 (p19/p40) (Kopp et al., 2003).  These animals developed inflammatory 
skin lesions with marked epidermal hyperplasia and increased levels of DC and T cell 
derived cytokines similar to those found in psoriasis lesions.  Thus, IL-23 appears to be 
an important “up stream” inflammatory product leading to synthesis of “down stream” 
genes controlled by IL-17 (STAT3 and neutrophil chemokines) and IL-22 (upregulation 
of antimicrobial peptides and downregulation of keratinocyte maturation genes) 
(Nograles et. al., submitted). 
 
Interferon regulatory factor-2 knockout model:  Interferon (IFN)-induced genes 
are transcribed by several types of transcription factors, including STAT1 and IFN 
regulatory factors (IRFs). IRF-1 is a transcriptional activator whereas IRF-2 suppresses 
IRF-1 activity. Hida et al have engineered an IRF-2 null mouse that chronically over 
expresses IRF-1 (Hida et al., 2000). These mice spontaneously develop inflammatory 
skin lesions similar to psoriasis including CD8+ T cell infiltration in the epidermis, CD4+ 
T cells in the dermis, and marked epidermal hyperplasia, implicating IFNγ as another 
important mediator of psoriasis. 
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Xenograft models:  Another approach that has yielded useful information has 
been to transplant unaffected (non-lesional) skin or lesional skin from a psoriasis patient 
on severe combined immunodeficiency (SCID) mice (Boehncke et al., 1994).  Injection 
of cytokines into the uninvolved tissue grafts induces some mild hyperplasia whereas 
injection of superantigen-activated mononuclear leucocytes obtained from peripheral 
blood of the same patient induces a full psoriasis phenotype (but without neutrophil 
infiltration), suggesting that the psoriasis phenotype can be induced in genetically 
predisposed skin by bacterial antigen primed leukocytes (Wrone-Smith and Nickoloff, 
1996). When psoriasis lesional skin is grafted, long-term grafts continue to show viable T 
cells and other mononuclear leukocytes. Thus, in this model it appears that T cells can 
continue to expand in situ in skin lesions at a rate that matches the rate of programmed 
cell death, and one does not need new T cells from the peripheral circulation to 
perpetuate the lesion. 
 
Perhaps of greater importance has been the observation that when non-lesional 
“normal” skin from psoriasis patients are grafted on to highly immunodeficient AGR129 
mice, the bystander T cells in the graft expand in situ and cause a full blown psoriatic 
lesion (Boyman et al., 2004).  Unlike SCID mice, AGR129 mice lack both NK cells and 
IFN receptors, which may leave them unable to reject graft T cells and/or create a 
cytokine environment more conducive to T cell activation.  Also of interest is the fact that 
either anti-TNF or anti-CD3 antibodies can block the onset of these lesions.  More 
recently, this model was used to show dependence of psoriatic phenotype on invasion of 
T cells into the epidermis (Conrad et al., 2007). 
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Pathogenic insights provided by genetics   
Twin studies suggest that there is a strong genetic component to psoriasis.  Over 
ten gene mapping studies have been performed on families with high prevalence of 
psoriasis in the USA and Netherlands, indicating there are at least 17 susceptibility genes 
(Bowcock, 2004).  One of the most compelling susceptibility genes is human leukocyte 
antigen (HLA)-Cw*0602 which was found in 10% of healthy controls and 50% of 
psoriasis patients (Nair et al., 2000).  HLA-Cw is a likely convergence between genetic 
linkage studies and psoriasis pathophysiology because it is an HLA class I molecule that 
can bind type A strep and has a strong association with psoriasis triggered by 
streptococcal pharyngitis.  T cells in the tonsil are almost exclusively skin homing, thus it 
is possible that HLA-Cw T cells reacting to strep have antigenic mimicry with an 
epidermal self-antigen (Elder, 2005, 2006).  Finally, a susceptibility region (PSORS2) 
has been mapped to a discrete DNA sequence.  PSORS2 is shown to encode a mutated 
binding site for the transcription factor RUNX1. Two adjacent genes, SCL9A3R1/EBP50 
and RAPTOR, each associated with activation-related signal transduction, may be 
affected in a way that leads to T cell activation or keratinocyte hyperplasia, but more 
work is needed to fully understand the functional consequences of this mutation.  Other 
susceptibility loci for psoriasis are found on chromosomes 1q21, 3q21, 4q, 7p, 8, 11, 16q, 
17q, and 20p (Bowcock, 2005).   
 
More recently, large linkage studies from multiple groups have shown that 
psoriatic patients are more likely to carry certain polymorphisms in their IL-23/IL-12 p40 
subunit and IL-23R genes compared to controls (Capon et al., 2007; Cargill et al., 2007; 
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Liu et al., 2008).  Researchers speculate that the alternative allele may be protective 
against psoriasis, and that the psoriatic allele is permissive.  Indeed, the IL-23 pathway is 
important for psoriasis pathogenesis as described in detail throughout this thesis. 
 
Psoriasis and autoimmunity 
While psoriasis is commonly referred to as an autoimmune disease, the strict 
definition of autoimmunity requires that the immune system react against host antigen(s).  
Although these autoimmune antigens have not yet been identified, it is clear that the 
psoriatic cellular immune response is overactive either due to auto-antigen mimicry or 
innate immune disregulation that does not require a host antigen catalyst.  The existence 
of an auto-antigen may be inferred from clonal T cells isolated from psoriatic plaques 
(Diluvio et al., 2006).  This theory is also appealing because it fits with the model of 
other common chronic inflammatory diseases, particularly arthritis where there is 
mimicry of bacterial peptides or lupus where dsDNA appears to be an immunogen.  It 
does not fit, however, with the immunohistochemistry staining of psoriasis lesions that 
reveal very few B cells in lesional skin compared with a vast influx of dendritic cells and 
T cells.  Autoimmune diseases like arthritis or lupus with isolated antigens have a large B 
cell component at the site of injury (Yurasov et al., 2005).   
  
Evolving theory of immunopathology 
The earliest studies on psoriasis concluded from the histology that it was a disease 
caused by hyperproliferative keratinocytes (Farber and McClintock, 1968).  Only when 
immunomodulating therapies targeting T cell influx into the tissue proved effective did 
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researchers focus on an overactive cellular immunity as the primary cause of disease 
(Gottlieb et al., 1995).  Recently it has been noted that psoriatic plaques contain an equal 
number of DCs  as T cells distributed throughout the epidermis and dermis.  Moreover, as 
with T cells, decrease in DC numbers corresponds with plaque clearance during treatment 
(Nickoloff and Stevens, 2006).  Affymetrix expression data shows that more dendritic 
cell genes are disregulated in psoriasis lesions than T cell lineage genes (Haider et al., 
2007).  Another indication that psoriasis may be in part a DC-mediated disease, is that 
TNF inhibitors reliably clear psoriatic skin plaques.  TNF and TNF receptors are not 
found at high levels on T cells but are found on monocyte derived dendritic cells 
(Gottlieb et al., 2005).  Recent work on mouse models has identified a type of DC termed 
the TNF and inducible nitric oxide synthase (iNOS)-producing dendritic cell (Tip-DC) 
that has activated NFκB and STAT transcription factor signal transduction pathways 
(Serbina et al., 2003).  The upstream regulators of these transcription factors are TNF and 
IFNγ/IL-17 respectively.  Thus, TNF inhibitors may inhibit TIP-DC function or 
maturation, shifting the immune response away from the pathogenic T cell response.  An 
in depth description of DC and T cell subsets in normal skin in now presented followed 
by a description of DC and T cell subsets in inflammatory psoriatic lesions. 
 
Human cutaneous DC subsets during-steady state and inflammation 
 
Cells with long dendrites were first described in the epidermis of the skin by 
medical student Paul Langerhans nearly 140 years ago (Langerhans, 1868). It was not 
until 1973 that the term “dendritic cell” was coined as these cells were effectively re-
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discovered by Ralph Steinman and Zanvil Cohn (Steinman and Cohn, 1973). These DCs 
were identified as potent antigen presenting cells (APCs) in the mixed leukocyte reaction 
(MLR). However, it took a number of years for scientists to appreciate the significance 
and potential roles of these cells, and we now know that they are central in generating 
and regulating immune responses.  
 
DCs are a heterogeneous population of cells in the immune system, defined 
initially by their appearance, but more specifically by their potent ability to present 
antigen to T cell. Standardized characterization of human cutaneous DC populations is 
complicated by pleomorphic phenotype and function during emigration from the skin for 
ex vivo study, and by the great number of potential surface and intracellular antigens that 
are present on these leukocytes. In addition, there are differences between human and 
murine DC networks. DC populations have been historically classified either spatially 
(circulating blood DCs, draining lymph node DCs, epidermal DCs, and dermal DCs), by 
their presumed origin (myeloid DCs, plasmacytoid DCs [pDCs]), by physiological or 
pathophysiological state (steady-state DCs, inflammatory DCs), or by antigen expression 
(Langerin, DEC-205 etc.). There are three cutaneous DC populations in the steady state – 
epidermal Langerhans cells (LCs), resident dermal myeloid DCs, and pDCs – and during 
inflammation there appears to be an additional population of myeloid dermal 






LCs were the first DC subset described (Langerhans, 1868). They reside in the suprabasal 
layers of the epidermis wedged in between, and in close contact with, keratinocytes. The stellate 
appearance of these cells led researchers to believe that they were of neural origin until over 100 
years later, when their role in antigen presentation was elucidated (Braathen and Thorsby, 1980). 
LCs were initially identified by the electron-dense organelle, the Birbeck granule, which has a 
unique tennis-racket appearance. The function of Birbeck granules is still unclear, but likely 
includes receptor-mediated endocytosis and transport of cellular materials into the extracellular 
space (Mc Dermott et al., 2002). The first monoclonal antibody that clearly identified LCs was 
CD1a, an MHC-I-like molecule that presents microbial lipids to T cells (Barral and Brenner, 
2007). More recently, the monoclonal antibody Langerin/CD207 has been used to specifically 
recognize LCs (Figure 2). Langerin/CD207 is a membranous C-type lectin that recognizes 
mannosylated ligands found on the surface of a wide range of pathogens including viruses, 
bacteria, fungi, and protozoa (Figdor et al., 2002).  Following receptor mediated endocytosis, 
CD1a and Langerin/CD207 traffic to the Birbeck granule where they may participate in antigen 
processing (Stossel et al., 1990). 
 
Elegant studies by Merad et al. have shed light on the origin and trafficking of LCs 
during steady state and inflammation (Merad et al., 2004; Merad et al., 2002).  It now seems 
clear that epidermal LCs are continuously replaced from a resident precursor pool (perhaps by 
self-renewal) throughout life under steady-state conditions (Merad et al., 2002). However, LCs 
are repopulated by blood precursors, most likely monocytes, following inflammation (Ginhoux 
et al., 2006).  In human psoriasis vulgaris, there are variable reports of the number and 
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arrangement of LCs in the epidermis adjacent to non-inflamed epidermis. This may be due to 
different staining and counting methods used for analysis, or non-equivalent patient populations. 
In our studies on stable plaque psoriasis, we have found that LCs in lesional and non-lesional 
epidermis are of similar number per linear surface, with a redistribution to the upper layers of the 
thickened psoriatic epidermis, and express comparable antigen markers (unpublished data). 
These observations are supported by studies showing that LC migration in psoriasis is impaired, 
leading to retention of LCs in psoriatic inflammation (Cumberbatch et al., 2006). Further studies 
need to be performed to evaluate LCs during human disease states using these new markers.  
 
Interest in LCs has increased with two key observations. Firstly, in mice, there is a newly 
discovered population of Langerin+ DCs in the dermis and skin draining lymph nodes (Bursch et 
al., 2007; Douillard et al., 2005; Ginhoux et al., 2007; Poulin et al., 2007; Stoitzner et al., 2003; 
Stoitzner et al., 2005). These epidermal and dermal LC populations have distinct phenotypic and 
mitotic capacities, and the dermal Langerin+ LCs do not appear to be simply epidermal LCs en 
route to the draining lymph node. Epidermal LCs are Langerin+CCR6+CCR7+/-, radioresistant, 
slowly self-replicating (Merad et al., 2002), and are highly responsive to CCR6 agonist 
macrophage inflammatory protein (MIP)-3alpha (CCL20). In contrast, dermal LCs are 
Langerin+CCR2+CCR7+/-, radiosensitive, rapidly self-replicating, and are responsive to CCR2 
agonist monocyte chemoattractant protein (MCP)-1 (CCL2) (Bursch et al., 2007; Ginhoux et al., 
2007; Poulin et al., 2007). Langerin+CD1a+ dermal LCs may also exist in human skin (Angel et 
al., 2006), although we have not yet been able to identify many dermal LCs in normal or 
psoriatic skin in situ (Lowes et al., 2005a). Secondly, there is much debate concerning the 
pathophysiological role of LCs. Until recently it was assumed that cutaneous antigens were 
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locally processed by epidermal LCs which then migrate out of the skin into the draining lymph 
node for efficient antigen presentation to T cells. During this journey to the lymph node, the LCs 
change their surface phenotype and “mature”, simultaneously down-regulating antigen-
processing and acquiring improved ability for T cell co-stimulation (Larregina and Falo, 2005). 
Recent studies have questioned the biological significance of this pathway as antigen-specific T 
cell activation remains intact in LC deficient murine models (Bennett et al., 2005; Kaplan et al., 
2005; Kissenpfennig et al., 2005a; Mommaas et al., 1994; Ritter et al., 2004; Zhao et al., 2003). 
These new observations suggest that there is steady-state migration of LCs to skin-draining 
lymph nodes, perhaps to induce and maintain tolerance to cutaneous antigens (Steinman and 
Nussenzweig, 2002). Thus a working hypothesis is emerging whereby DCs that reside in the 
dermis may be essential for the process of cutaneous immune activation while LCs may play a 
more important role in sustaining cutaneous immunological tolerance. 
 
Dermal dendritic cells 
 The population of DCs that reside in the dermis of the skin are known as dermal 
DCs, and these are considered analogous to “interstitial DCs” found in the connective 
tissue and stroma of other organs (Shortman and Naik, 2007). As the potential 
redundancy of LCs for immune stimulation has emerged, there has been more interest in 
dermal DCs. These important cells have the capacity to take up cutaneous antigens, 
mature and migrate to draining local lymph nodes, and present these antigens to T cells 
and B cells (Dubois et al., 1998; Kissenpfennig et al., 2005b). Because culture methods 
change the surface cellular phenotype, the purest phenotypic classification of these DCs 
is best performed in situ, followed by ex vivo functional verification of antigen presenting 
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capacity. Unfortunately, there is no single or specific marker for these cells, although the 
integrin CD11c is probably the best tool we currently have to identify them. For many 
years, antibodies to Factor XIIIA (FXIIIA) clotting factor were used to identify a dermal 
population of cells which have multiple dendritic processes protruding from a stellate-
shaped cell body, and were thus called “dermal dendrocytes” (Headington, 1986).  In 
1993 Meunier et al. described a small population of HLA-DR+CD11c+CD1c+FXIIIA+ 
cells from cultured normal human dermis that had the capacity to stimulate T cells in a 
MLR (Meunier et al., 1993). In addition, Nestle et al showed that immunostimulatory 
dermal DC populations were present from psoriatic skin (Nestle et al., 1998; Nestle et al., 
1993).  However, it has recently been demonstrated that Factor XIIIA is induced with 
culture and is actually a macrophage marker, rather than a specific DC marker (D. 
Torocsik, 2005). Thus, more work needs to be performed to re-evaluate the body of 
literature classifying dermal APCs as FXIIIA+.  
 
Resident dermal DCs 
In order to understand dermal DCs and to develop working models to study these 
cells, we and others have developed the concept that there is a resident population of 
dermal DCs, as well as an additional group of DCs that appear or develop during 
inflammation (“inflammatory dermal DCs”) (Shortman and Naik, 2007). Resident murine 
steady-state dermal DCs (CD11c+) appear to be able to proliferate in situ to maintain this 
population (Bogunovic et al., 2006). The major resident population in normal dermis is 
identified phenotypically with a single monoclonal antibody, CD1c, which is also known 
as blood dendritic cell antigen (BDCA)-1.  BDCA antibodies -1, -2, -3, and -4 form a 
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group of proteins that were first used to identify circulating DCs (MacDonald et al., 
2002). In steady-state, BDCA-1+ DCs are relatively immature with modest T cell 
stimulatory ability, but their immunostimulatory capacity can be greatly increased with 
DC maturing stimuli (Zaba et al., 2007b).  These BDCA-1+ DCs are also CD11c+HLA-
DR+CD45+CD14lo, are mostly dendritic cell-specific ICAM-3-grabbing non-integrin 
(DC-SIGN)/CD209+, and by flow cytometric analysis, are approximately 50% CD1a+.  
CD1c+CD14-CD1a+ dermal DCs from normal skin are also CCR7+ and are responsive to 
the lymph node chemokine CCL19, suggesting that these cells can migrate to draining 
lymph nodes for antigen presentation (Angel et al., 2006). It is possible that these 
immature BDCA-1+ resident DCs are tolerogenic in steady state, analogous to epidermal 
Langerhans cells. 
 
While most of these BDCA-1+ cells are relatively immature, there is a small 
subgroup (~5%) expressing mature DC markers dendritic cell-lysosomal-membrane 
associated protein (DC-LAMP)/CD208 and DEC-205/CD205 (Zaba et al., 2007b).  These 
rare, phenotypically mature cells aggregate together in dermal clusters, but their scarcity 
prevents detailed functional analysis. Perhaps normal skin requires a small population of 
mature DCs for fast antigen presentation to local T cells.  
 
In normal skin, there is also a population of dermal DCs identified by BDCA-3. 
These BDCA-3+ cells constitute approximately 10% of all CD11c+ dermal DCs and do 
not overlap with BDCA-1+ DCs.  Again, functional analysis has not been performed on 
dermal BDCA-3+ cells due to their low frequency; however, it has been established that 
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BDCA-3+ DCs in blood are non-overlapping with blood BDCA-1+ DCs and are the least 
immunostimulatory myeloid blood DC population (MacDonald et al., 2002). 
 
Inflammatory dermal DCs 
Inflammation induces dramatic changes in dermal DC populations, most 
obviously a 30-fold increase in CD11c+ DCs in the dermis (approximately equal to T cell 
numbers) (Zaba et al., 2007a). These DCs return to normal or non-lesional levels with 
effective treatment (Lowes et al., 2005b; Zaba et al., 2007a). Characterization of these 
cells during inflammation is not yet complete, but our preliminary studies suggest that 
they are not BDCA-1+. This indicates that they may be derived from circulating DC- 
precursors migrating into the skin due to inflammatory and chemotactic signals. Potential 
precursors include circulating hematopoietic precursor cells (Massberg et al., 2007; 
Svensson and Kaye, 2006), circulating “pre-DCs” (CD11c+ HLA-DRhi, CD16+) (Piccioli 
et al., 2007; Randolph et al., 2002; Tacke and Randolph, 2006) monocytes (Serbina et 
al., 2003), or resident DCs.  
 
In psoriasis, we have been able to determine that dermal DCs produce mediators 
TNF and intracellular nitric oxide synthase (iNOS), and these have been termed TNF and 
iNOS-producing DCs (Tip-DCs) (Lowes et al., 2005a). Tip-DCs were first described in a 
murine model of Listeria monocytogenes infection (Serbina et al., 2003) and have also 
been found in murine E.coli bladder infection (Engel et al., 2006). In humans, the 
location and functions of Tip-DCs are emerging: they are present in the lamina propria of 
the gut where they may be important for IgA production (Tezuka et al., 2007), and they 
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appear to be induced by topical imiquimod treatment of basal cell carcinoma (Stary et al., 
2007), so they may participate in tumor rejection. Pathogenicity of these Tip-DCs in 
psoriasis is suggested by the rapid downmodulation of Tip-DC products TNF, iNOS, IL-
20, and IL-23 during effective treatment with effective therapies (Haider et al., 2008; 
Zaba et al., 2007a). We now hypothesize that the Tip-DC is a novel type of DC 
associated with inflammation that can directly mediate inflammatory processes, through 
innate immune pathways and associated cytokines such as IL-20 (Wang et al., 2006) and 
IL-23 (Zaba et al., 2007a). Tip-DCs can also stimulate the differentiation and activation 
of Th17 T cells (unpublished data), which are a new set of T cells associated with 
autoimmune inflammation in many disease models (Lowes et al., 2008). The potential 
role of these DCs as sources of inflammatory mediators is in contrast to the classic role of 
DCs as antigen-presenting cells, and warrants further attention. Because these DCs may 
actually be the key target of a variety of anti-inflammatory therapies, and may be broadly 
involved in "autoimmune" inflammation of many different human diseases, we need to 
better understand the development and activation of these cells.  
 
In another common skin disease, atopic dermatitis, a population of inflammatory 
DCs have also been described. These cells were initially termed inflammatory dendritic 
epidermal cells (IDECs) based on flow cytometric analysis of cells from epidermal cell 
suspensions (Novak and Bieber, 2005; Wollenberg et al., 1996; Wollenberg et al., 2002).  
IDECs were defined by the following: HLA-DR+Lin-CD11c+CD1a+ and these DCs co-
express CD206/macrophage mannose receptor (MMR), CD36, FcεRI, IgE, CD1b/c, 
CD11b, as well as DC-SIGN/CD209 (Guttman-Yassky et al., 2007). There is now 
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appreciation that these DCs are dermal and appear to produce a different array of 
cytokines and chemokines (Th2 chemokines CCL17 and CCL18) than do psoriatic 
inflammatory DCs, and do not have an iNOS signature (Guttman-Yassky et al., 2007). 
Thus the cutaneous inflammatory milieu may drive the differentiation of different types 




 PDCs are an additional unique population of resident cutaneous DCs initially 
described by their morphology, which is similar to a plasma cell (Corcoran et al., 2003). 
PDCs share many characteristics with B cells, including dependence on a B cell 
transcription factor (SPI-B), and immunoglobulin gene rearrangements. It now appears 
that both PDCs and myeloid DCs may actually arise from a bone marrow-derived 
common DC precursor (Naik et al., 2007; Onai et al., 2007).  While both myeloid and 
plasmacytoid DCs express high levels of HLA-DR and have the capacity to present 
antigen, pDCs are characterized by their ability to produce large amounts of type 1 
interferon (IFN) (IFN-α, β, ω) during viral infection – 10,000 fold more IFN than any 
other cell type (Ito et al., 2004; Kadowaki et al., 2000). This potent IFN production is 
induced by viral RNA and DNA containing repeated unmethylated CG nucleotides 
binding to Toll-like receptor (TLR) 7 and TLR9 endosomal receptors.  IFN-α, the most 
studied of the Type I IFNs, modulates development and maturation of many immune 
cells, including T cells and myeloid DCs, by binding to abundantly expressed IFN 
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receptor (Theofilopoulos et al., 2005). The pleiotropic effects of pDC activation are 
complicated and not fully understood. 
 
 Monoclonal antibodies for pDC identification are well developed and include 
CD123/IL-3R, BDCA-2, and BDCA-4.  BDCA-2 is the only marker that is exclusive to 
pDCs, as myeloid DCs can express low levels of CD123 and BDCA-4 (Liu, 2005).  Thus, 
a common phenotypic definition of blood and tissue pDCs is HLA-DR+CD11c-
CD123hiBDCA-2+. Research on the function of human pDCs during steady-state and 
disease is limited by low frequency and transitory expression of IFNα (Nestle and Gilliet, 
2005).  
 
In our studies of normal skin, we find a small number of pDCs (Zaba et al., 
2007b), and there does not appear to be any marked increase in the frequency of these 
cells in chronic large plaque psoriasis (Guttman-Yassky et al., 2007), although others 
have found an increase of these cells in psoriasis (Nestle et al., 2005). However, two 
recent observations support a role for pDCs during the initiation phase of psoriasis. 
Firstly, in xenotransplant experiments of non-lesional skin from patients with psoriasis 
grafted onto immunosuppressed mice, the stress of transplantation is sufficient for 
psoriasis to develop spontaneously in the graft. Blockade of IFN-α prevented 
development of psoriasis, implicating pDCs as they are the primary source of IFN-α in 
the skin (Nestle and Gilliet, 2005).  Secondly, keratinocyte peptide LL37 (also known as 
cathelicidin or cathelicidin antimicrobial peptide [CAMP]), binds to self-DNA and TLR9 
in pDCs, and induces IFN-α (Lande et al., 2007).  Expression of this antimicrobial 
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peptide is increased during inflammation such as psoriasis, and down-stream effect of 
this increased IFN-α production may be activation of myeloid DCs and initiation of 
psoriasis (Farkas et al., 2001; Nestle and Gilliet, 2005). Patients with psoriasis may have 
pDCs that are particularly sensitive to LL37 and respond in an exaggerated manner with 
increased IFN-α induction, thus setting in motion psoriatic inflammation.  
 
TH17 T cells as mediators of psoriasis pathogenesis 
 
Until recently, IFNγ-producing Th1 T cells were implicated as the main 
pathogenic cells (Blauvelt, 2007) as certain T cell-targeted therapies were successful in 
clearing psoriasis (Lowes et al., 2007), and clonal T cells have been found in psoriatic 
skin (Prinz et al., 1994).  However, we are beginning to appreciate that there may be an 
important pathogenic contribution from a recently-recognized subset of T cells – Th17 
cells producing IL-17 and IL-22 (Bettelli et al., 2007; Blauvelt, 2007).  In model systems, 
IL-17 stimulates keratinocyte production of innate inflammatory “danger signals” such as 
defensins and S100 proteins as well as IL-8 neutrophil chemokine (Liang et al., 2006), 
while IL-22 induces S100 innate defense proteins (Wolk et al., 2006) and keratinocyte 
hyperproliferation (Sa et al., 2007; Zheng et al., 2007).  Upstream inducers of Th17 cells 
are still being understood, as most experiments have been performed in murine model 
systems.  Mediators may include IL-1, IL-6, and TGFβ, which stimulate differentiation of 
naïve CD4+ T cells into activated memory Th17 cells (Annunziato et al., 2007; Mangan 
et al., 2006; Sutton et al., 2006), and IL-23 which drives Th17 proliferation (Vanden 
Eijnden et al., 2005). 
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Th17 T cells producing IL-17 and IL-22 have been implicated as pathogenic in 
murine models of autoimmune diseases, such as experimental autoimmune 
encephalomyelitis (EAE), collagen-induced arthritis (CIA), and inflammatory bowel 
disease (IBD) (Granelli-Piperno et al., 2005; Komiyama et al., 2006; Nakae et al., 2002; 
Nakae et al., 2003). IL-17 knockout mice are resistant to both EAE and CIA.  Also, mice 
with EAE have increased numbers of Th17 cells, but are resistant to disease if immunized 
against IL-17 (Uyttenhove and Van Snick, 2006).  The DC product IL-23, a survival 
factor for Th17 cells, also appears to be necessary for IBD pathogenesis in mice (Yen et 
al., 2006).  Thus a model is emerging of autoimmune inflammation that begins with 
activated APCs producing IL-23, subsequent Th17 cell proliferation and IL-17/IL-22 
release, and downstream inflammatory tissue damage.  
 
Most studies on Th17 cells have been performed in murine models or in vitro. 
However, there is some human data also supporting a similar model of Th17-mediated 
autoimmune inflammation.  Patients with IBD have elevated IL-17 and IL-22 in affected 
colonic tissue and serum, dependent on disease activity and severity (Fujino et al., 2003; 
Nielsen et al., 2003; Te Velde et al., 2006), and patients with rheumatoid arthritis (RA) 
have elevated IL-17 and IL-22 protein in synovial fluid (Ikeuchi et al., 2005; Kotake et 
al., 1999).  In psoriasis patients, IL-17 mRNA has been demonstrated within lesions (Li 
et al., 2004), but protein levels are not increased in the serum (Arican et al., 2005).  IL-22 
protein is increased in psoriatic serum compared to normal, and mRNA is increased in 
lesional tissue (Wolk et al., 2006).  High levels of IL-23 have also been detected in 
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psoriasis lesions (Piskin et al., 2006), and are strongly diminished by effective therapies 
for psoriasis (Lowes et al., 2005b). 
 
Anti-inflammatory and immune modulating effects of TNF inhibition in psoriasis  
 
 Psoriasis drug treatment falls into two basic categories:  general 
immunosuppressive drugs (cyclosporine) and targeted immunomodulating drugs (anti-
CD2, anti-CD11a, anti-TNF).  The systemic immunosuppressive drugs tend to have 
major side effects such as general immunosupression and kidney failure (Andoh and 
Bennett, 1998; Bennett, 1998), whereas the targeted immunotherapy has a unique side 
effect profile for each drug.  The effectiveness of each drug is also variable and 
unpredictable.  Currently, TNF blockers have become a front-line drug for treatment of 
moderate to severe psoriasis (Strober, 2005). 
 
Two anti-TNF drugs are currently in use in the clinic: etanercept (Enbrel, Amgen) 
is a TNF/lymphotoxin antagonist fusion protein consisting of the extracellular domain of 
the low affinity TNF-RII and immunoglobulin constant region domain, and infliximab 
(Remicade, Johnson & Johnson) is a chimeric antibody with a mouse Fab fragment raised 
against human TNF, fused with a human Ig constant region.  Etanercept effectively 
improves psoriasis in 60-70% of patients depending on the drug regimin (Gottlieb, 2004; 
Gottlieb et al., 2005), and infliximab is slightly more effective for first time users of the 
drug, although development of human anti-mouse antibodies frequently prevent a second 
drug course.  Mechanism of action of these drugs is complicated, as both the Fab 
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fragment and Fc portion of the antibodies can modulate immunity and TNF is a global 
cytokine produced by many cells in abundance.  The primary mechanism of action for 
etanercept is still unknown, although we postulate that a primary effect of etanercept is 
that it blocks TNF that would otherwise lead to maturation of dermal DCs and 




 Psoriasis is a rapidly changing field, facilitated by relatively easy access to the 
diseased organ (human skin), and by immune modulating drugs effectively creating 
human knock-out models.  Elucidation of the physical and chemical interactions between 
DCs and T cells is important for undertanding psoriasis immunopathogenesis and 
creation of more specific immune modulating therapies.  Effective clinical trials using 
TNF or IL-12/IL-23 p40 subunit blockers demonstrate that DC activation products and 





CHAPTER 2 :  Materials and methods 
 
Skin samples  
 
Normal skin. Skin punch biopsies (6 mm diameter) were obtained from 15 normal 
volunteers under a Rockefeller University IRB-approved protocol. Informed consent was 
obtained. Biopsies were frozen in OTC (Sakura) and stored at –80°C for 
immunohistochemistry and immunofluorescence. Normal samples from abdominoplasty 
were processed within 4 hours post-surgery. These abdominoplasty samples were also the 
source of tattoo material.  Dermal single cell suspensions from normal skin were obtained 
using a modified collagenase/dispase method (Angel et al., 2006). Subcutaneous fat was 
excised and remaining tissue was washed with PBS. The dermal layer was heavily scored 
with a scalpel and incubated in 1 mg/ml type 1 collagenase (Invitrogen Life 
Technologies), 1 mg/ml dispase (Invitrogen Life Technologies), and 1% penicillin-
streptomycin solution (Sigma) overnight at 37°C. The epidermis was peeled off and 
discarded, and the dermis was transferred to fresh RPMI 1640 supplemented with 10% 
pooled human serum (Mediatech Inc.), 0.1% gentamicin reagent solution (Gibco-BRL 
Life Technologies), and 1% 1M Hepes buffer (Sigma). The dermis was incubated 24-48 
hrs at 37°C and the supernatant was collected and filtered with 40-µm cell strainers (BD 
Biosciences). Cells were then either used immediately for MLR, or frozen in RPMI 1640 
(Gibco-BRL Life Technologies) and 10% DMSO (ATCC) for FACS.  
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Psoriasis skin samples for etanercept clinical trail. Twenty adult patients with 
moderate to severe psoriasis were treated with etanercept 50mg subcutaneously twice 
weekly (BIW) for 12 weeks under a Rockefeller University IRB approved protocol.  
Patients did not receive topical or systemic psoriasis therapy for a minimum of 1 month 
before dosing.  No patient was experiencing flare at the initiation of etanercept 
treatment.  At baseline, 6mm (diameter) punch biopsies were taken from an uninvolved 
area (non-lesional) and from an index psoriasis lesion.  Punch biopsies were obtained 
again from the index lesion at weeks 1, 2, 4, and 12 of etanercept treatment.  All 
biopsies were cut in half – one piece was frozen in liquid nitrogen for RNA extraction, 
and the other was frozen in cutting media for immunostaining.  1cm2 shave biopsies 
used for FACS analysis on dermal émigrés were obtained from lesional areas at 
baseline and week 2.  Patients were classified as histological responders based on 
frozen section epidermal thickness, K16 immunostaining, and Ki67 cell counts 
decreasing to non-lesional magnitude by week 12 (Gottlieb et al., 2005).   
 
Cell phenotyping assays 
 
Antibodies.  All antibodies used for immunohistochemistry, immunofluorescence and 
FACS are listed in Tables 1 and 2. 
 
Immunohistochemistry. Skin sections were stained with primary antibodies listed in Table 
1.  Biotin labeled horse anti-mouse, and biotin labeled rabbit anti-sheep antibodies 
(Vector Laboratories) were used to detect mouse monoclonal and rabbit polyclonal 
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antibodies, respectively. The staining signal was amplified with avidin-biotin complex 
(Vector Laboratories) and developed using chromogen 3-amino-9-ethylcarbazole (Sigma 
Aldrich). Positive cells per mm were counted manually using computer-assisted image 
analysis (NIH IMAGE 6.1).  Appropriate negative controls were used. 
 
Immunofluorescence. Skin sections were fixed with acetone and blocked in 10% normal 
goat serum (Vector Laboratories) for 30 mins. Primary antibodies (listed in Table 1) were 
incubated overnight at 4°C, and amplified with the appropriate secondary antibody: goat 
anti-mouse IgG1 conjugated with Alexa Fluor 488 or 568, or donkey anti-sheep 
conjugated with Alexa Fluor 488 or 568, respectively. For co-localization, sections were 
co-stained overnight with a second antibody (listed in Table 1), and amplified with the 
appropriate goat-anti mouse secondary antibody. Images were acquired using a Zeiss 
Axioplan 2I microscope with Plan Apochromat 20 X 0.7 numerical aperture lens and a 
Hagamatsu orca ER-cooled charge-coupled device camera, controlled by METAVUE 
software (Universal Imaging). Dermal collagen fibers gave green autofluorescence. 
Antibodies conjugated with a fluorochrome often gave background epidermal 
fluorescence. Images in each figure are presented both as single color stains (green and 
red) so that one can easily appreciate the localization of two markers on similar or 
different cells. Single stains are above the merged images. Cells that co-express the two 
markers in a similar location are often yellow in color.  
 
FACS. Cells were stained with the antibodies listed in Table 2. Briefly, cells were stained 
for 20 mins at 4°C, washed with FACSwash (PBS 0.1% sodium azide and 2% FBS) and 
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resuspended in 1.3% formaldehyde (Fisher Scientific) in FACSwash.  For intracellular 
cytokine staining assays, cells were activated in RPMI for 4 hours using 25 ng/ml 
phorbol myristate acetate (PMA) and 2 µg/ml ionomycin, in the presence of 10 µg/ml 
brefeldin A (all Sigma Aldrich) at 37°C.  Unactivated controls were treated with brefeldin 
A only.  Ethylenediaminetetraacetic acid (2 mM, Fisher Scientific) was added for 10 min. 
at 37°C to stop activation. Cells were then incubated in aqua marina live/dead dye (BD 
Biosciences) for 30 min. on ice, washed, fixed with 4% paraformaldehyde (BD 
Biosciences) for 20 min. on ice, blocked in 1:100 mouse serum (BD Biosciences), 
permeabilized in FACSPerm (BD Biosciensces), incubated simultaneously with 
intracellular cytokine and extracellular antibodies, washed, and collected.  Samples were 
acquired using either a FACSCanto or LSR-II (both BD Biosciences) and analyzed with 
FlowJo (Treestar). Appropriate isotypes and unactivated controls were used. 
 
Electron Microscopy. Skin was fixed in 2.5% glutaraldehyde and processed by routine 
transmission electron microscopy procedure. Semi-thin plastic sections were stained with 
toluidine blue for light microscopic evaluation. Ultra-thin (65nm) sections were cut with 
a diamond knife, collected on copper grids, stained with both uranyl acetate and lead 
citrate before viewing in a Tecnaispirit electron microscope (FEI Company) equipped 
with Ultrascan 895 CCD camera (Gatan). 
Functional assays 
 
FACS sort and Mixed Leukocyte Reaction (MLR) using BDCA-1+ or CD163+ cells from 
normal dermal émigrés. Dermal cells from single cell suspensions of normal skin were 
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stained with BDCA-1, CD19, and CD163 antibody and sorted on a FACSAria (BD 
Biosciences) using a low-pressure setting. Two populations were obtained: BDCA-
1+CD19- and CD163+. A post-sort collection was performed to confirm the purity of each 
stimulating population. For some experiments, sorted cells were cultured for 2 days with 
and without cytokines for maturing DCs ex-vivo (IL-1β, IL-6, TNF-α, PGE2), then 
washed and prepared for the MLR. 
 Responding T cells were obtained from a normal volunteer by density 
centrifugation over Ficoll-Paque Plus (Amersham Biosciences), followed by T cell 
purification using a T cell negative selection kit (Dynal). T cells were labeled with 10µm 
CFSE and co-cultured with either BDCA-1+ or CD163+ sorted cells at 1:10, 1:50, or 
1:100, depending on cell yield. T cells without a stimulator population were used as a 
negative control, and monocyte-derived mature DCs were added to T cells as a positive 
control. The process for making mature DCs was previously described (Lee et al., 2002). 
T cell proliferation was analyzed on day 8 post-sort. The cultures were harvested, stained 
with 250 ng/ml propidium iodide (PI) to label dead cells, and CD3-APC (Becton 
Dickenson) for 15 mins at room temperature. PI negative cells were gated and then 
plotted as CFSE versus CD3+ cells, where proliferating cells diluted their content of 
CFSE and move to the left of the non-proliferating cells. The CFSE low cells were 
quantified as a percentage of live cells in the culture (Parish, 2001).  
 
FACS sort and MLR using BDCA-1+, BDCA-1- or CD163+ cells from psoriatic dermal 
émigrés. Dermal cells from single cell suspensions of psoriasis shave biopsies were 
stained with BDCA-1, CD163, CD11c, and HLA-DR antibodies and sorted on a 
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FACSAria using a low-pressure setting. Three populations were obtained: CD163+, 
CD11c+HLA-DR+BDCA-1+ and CD11c+HLA-DR+BDCA-1-. A post-sort collection was 
performed to confirm the purity of each stimulating population.  An MLR was performed 
as described for cells obtained from normal skin.  
 
In vitro TNF neutralization assays. The process for making monocyte derived DCs 
(moDCs) has been previously described (Dhodapkar et al., 2002).  All analysis was 
performed on “day 5” immature DCs.  Etanercept 10µg/mL was added to experimental 
wells on days 0, 2, and 4.  We chose this concentration of etanercept as it approximates 
the plasma concentration of drug when given 50mg BIW. Three biological replicates of 
each condition were prepared.  For the MLR, responding T cells were obtained from a 
normal volunteer by density centrifugation over Ficoll-Paque Plus (Amersham 
Biosciences), followed by T cell purification using RosetteSep (StemCell Technologies). 
T cells for cytokine FACS staining were purified from peripheral blood using T negative 
select beads (Dynal), activated using PMA and ionomycin as previously described 
(Vugmeyster et al., 2004), and cultured for 24 hours +/- etanercept 10µg/mL.  Three 
biological replicates of each condition were prepared.   
 
P40 neutralization and T cell polarization assays.  Dermal émigrés from 3 psoriatic 
patients were cultured with donor T cells (with or without CFDA) (1:10) and IgG isotype 
or anti-p40 monoclonal antibodies (10ug/mL) for 8 days.   Cells were activated using 
PMA and ionomycin and golgi-stopped using BFA.  Non-CFDA loaded cells were 
stained using live-dead assay, CD3, CD4, CD8, IFNγ, IL-17, and IL-4 and analyzed using 
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the LSRII FACS machine (BD Biosciences).  CFDA cells were stained with PI and CD3 
as previously described. T cells alone were used as a negative control, and T cells 
stimulated with CD3/28 beads (Dynal: 1/2 bead per T cell) were used as a positive 
control.  
 
Luminex.  T cell polarization assay plates were centrifuged and the supernatant collected 
for measurement of cytokine protein concentration using the human cytokine 25-plex kit 
(Invitrogen) on a luminex CS1000 autoplex analyzer (Luminex corporation).  The assay 
was performed in duplicate according to the manufacturer's instruction, and results were 
averaged. 
 
Primary keratinocyte cultures.  Primary pooled human keratinocytes (n=3) were obtained 
from Yale Skin Diseases Research Center core facility and cultured in RPMI 1640 with 
10% pooled human serum, 0.1% gentamicin reagent solution, and 1% 1M Hepes buffer at 
37°C as above.   Once 80% confluent, media was supplemented with or without 
cytokines rh-IL-17 (R&D) 200ng/ml, rh-IL-22 (Peprotech Inc.) 200 ng/ml, or rh-IFNγ 
(R&D) 20 ng/ml, for 24 hours before harvesting for other analyses. 
 
RNA assays 
   
RNA extraction and gene array processing.  Tissue and cell line RNA was extracted 
using the RNeasy Mini Kit (Qiagen), DNA was removed with on-column DNAse 
digestion using RNAse-free DNAse Set (Qiagen), and used for either RT-PCR or gene 
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array.  For each affymetrix genechip, 4µg total RNA was reverse-transcribed, amplified, 
and labeled as described previously using BioArray High Yield RNA Transcription 
Labeling Kit (Enzo Biochem Inc.) (Zhou et al., 2003).  15µg of the biotinylated cRNA 
was then hybridized to Affymetrix Human Genome U133A 2.0 Array (14,500 probe sets) 
(Affymetrix Inc.).  The chips were washed, stained with streptavidin-phycoerythin, and 
scanned with an HP GeneArray Scanner (Hewlett-Packard Company).  Raw fluorescence 
intensity values were analyzed using GeneChip Operating software version 1.2 
(Affymetrix) and GeneSpringTM.  Data for triplicates were averaged.  Array files are 
deposited at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9239 
 
RT-PCR.  RT-PCR was performed using EZ PCR core reagents, primers, and probes 
(Applied Biosystems) as previously published (Chamian et al., 2005).  The primers and 
probes for TaqMan RT-PCR assays for K16, inducible nitric oxide synthase (iNOS), IL-
23p19, IL-12/IL-23p40, IFNγ, IL-8, and human acidic ribosomal protein (HARP) were 
also previously published (Chamian et al., 2005).  Sequences of other primers and probes 
used in these studies were as follows: CCL20 (MIP-3α) forward 
GCTTTGATGTCAGTGCTGCTACTC, CCL20 reverse 
GTATCCAAGACAGCAGTCAAAGTTG, CCL20 probe FAM- 
TGCGGCGAATCAGAAGC AGCAA-TAMRA, IL-6 forward 
CCAGGAGCCCAGCTATGAAC, IL-6 reverse CCCAGG GAGAAGGCAACTG, IL-6 
probe FAM-CCTTCTCCACAAGCGCCTTCGGT-TAMRA, IL-4 forward 
CGACTGCACAGCAGTTCCA, IL-4 reverse AGGTTCCTGTCGAGCCGTTT, IL-4 
probe FAM-AGGCACAAGCAGCTGATCCGATTCC-TAMRA, IL-20 (ABI assay # 
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Hs00218888_m1), IL-12p35 (ABI assay # Hs00168405_m1), LTA-1 (ABI assay # 
Hs00236874_m1), MX-1 (ABI assay #  Hs00182073_m1), IL-17A (ABI assay # 
Hs00174383_m1), IL-22 (ABI assay # Hs00220924_m1), defensin (ABI assay # 
Hs00175474_m1),  IL-1β (ABI assay # Hs00174097_m1), and TGFb1 (ABI assay # 
Hs00171257_m1).  The data were analyzed and samples quantified by software provided 
with the Applied Biosystems PRISM 7700 (Sequence Detection Systems, ver. 1.7).  Data 




ANOVA.  All clinical variables were analyzed using Repeated Measures ANOVA models 
using the MIXED procedure available in SAS.  The within-subjects correlation that best 
modeled the data was an AR (1) structure that considered each time measurement as 
dependent on the previous one.  Differences between Lesional (Baseline) and weeks 1, 2, 
4, and 12 were estimated, and the one-tail p-values are designated as p<0.05 (*), p<0.01 
(**), and p<0.001 (***).   
 
Etanercept clinical trial gene array analysis 
 
Array quality control, preprocessing and filtering.   GeneChip CEL files were scrutinized 
for spatial artifacts using Harshlight package 
(http://asterion.rockefeller.edu/Harshlight/index2.html) (Suarez-Farinas et al., 2005). 
Classical microarray quality control report was obtained using affyQCReport package 
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from Bioconductor.  Intensity values (CEL files) were pre-processed to obtained 
expression values using GCRMA algorithm. Expression values were filtered to eliminate 
probesets with low variation or intensity.  Probesets with standard deviations greater than 
0.15, and expression values greater than 4 in at least 5 samples, were kept for further 
analysis. Affy control probes were also eliminated. A total of 12,864 probesets passed 
these filters.  
 
Differential Expression Criteria: The etanercept clinical trial was a repeated measures 
time course model with a between factor Group (Responders/ Non-Responders). A linear 
model with Time, Group, TimexGroup and Patient as random effect was considered. 
Model fitting and hypothesis testing were conducted using the limma package form 
Bioconductor (Wettenhall and Smyth, 2004).  Limma uses an empirical method to 
moderate the standard errors of the estimated comparisons, resulting in more stable 
inference and improved power. All hypotheses tested were derived from this model.  For 
each hypothesis, the p-value of the corresponding statistic (F or t) was adjusted for 
multiple hypothesis testing, controlling the false discovery rate (FDR) using the 
Benjamini-Hochberg procedure.  Additionally, to determine if individual comparisons 
were significant, FDR adjustments were made across genes.  
To determine disease related genes, a moderated t-test was used between non-
lesional (NL) and lesional (LS) measures.  To identify genes that varied across time for 
responders, a moderated F test was used to determine whether any of the expression 
values across time (weeks 1, 2, 4, and 12) differed from lesional baseline.  To determine 
 34 
genes with different time profiles among responders vs. non-responders (Interaction 
Term TimexGroup), we used an F test to identify significant interaction terms. 
 
Consensus Clustering:  The optimal number of clusters was assessed using Consensus 
Clustering (CC) algorithm available in GenePattern software (Monti et al., 2003).  To 
assess the stability of the discovered clusters, resampling techniques simulated 
perturbations of the original data. The clustering algorithm of choice was applied to each 
of the perturbed data sets, and the agreement (or consensus) among the multiple runs was 
assessed and summarized in a consensus matrix.  A distinct consensus matrix and 
summary statistics were generated for each cluster scenario.  Selection of the optimal 
number of clusters was done using the consensus matrix and the statistics associated with 
the empirical cumulative distribution (CDF) of the consensus matrix. The ideal partition 
had a clear consensus matrix and any further increase in the number of clusters did not 
lead to an increase of the area under the CDF. 
 
MuSTAT correlations.  In order to assess the correlation between IL-17/IL-22 or 
IFNγ/LTA-1 with epidermal thickness/K16/Ki67, the muStat package available in R 
(www.r-project.org) was used. U scores were computed for histological response and 
gene expression taking into account the clustered structure of the data (time points for 
each patient) as previously described (Wittkowski and Liu, 2002). Variables were 
normalized within patients in order to make all patients comparable. Correlation between 
the histological response score and the expression score were calculated and its 
significance is presented.
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Table 1: Antibodies used for immunohistochemistry and immunofluorescence 
 
 
Antigen Manufacturer Clone Dil 
CD11c BD Pharmingen B-ly6 1:100 
CD11c- A488 BD Pharmingen B-ly6 1:10 
Factor XIIIA Enzyme Research AP Polyclonal  
Sheep 
1:100 
HLA-DR-FITC BD L243 1:100 
DEC-205 Dr Steinman NA 1:100 
CD1a-FITC Pharmingen HI149 1:10 
Langerin Immunotech DCGM4 1:100 
DC-SIGN-FITC BD Pharmingen DCN46 1:50 
DC-LAMP-PE Immunotech 104.G4 1:50 
CD14-A488 BD Pharmingen M5E2 1:100 
BDCA-1  Miltenyi AD5-8E7 1:100 
BDCA-2 Miltenyi AC144 1:100 
CD123 BD 9F5 1:20 
CD206 GeneTex 15-2 1:100 
CD68 BD Pharmingen Y1/82A 1:100 
CD11b BD Pharmingen ICRF44 1:10 
CD45-FITC BD Pharmingen HI30 1:100 
FDC Dako Cytomation CNA.42 1:25 
CD163-FITC Acris 5C6-FAT 1:100 
Vimentin Lab Vision/ 
Neomarkers 
V9 1:100 
CD63-FITC BD Pharmingen H5C6 1:100 
RFD7 Abcam RFD7    1:100 
INOS-FITC BD Biosciences 6 1:50 
INOS Santa Cruz  N-20 1: 20 
TNF-α-FITC BD Biosciences 6401.1111 1:10 
K16 Sigma Aldrich K8.12 1:1000 
Ki67 Immunotech Mib-1 1:100 
CD3 BD Pharmingen Sk7 1:100 
CD83 BD Pharmingen HB15e 1:100 
IL-20 R&D Systems 158609 1:10 
IL-23/IL-12p40 R&D Systems 31052.11 1:50 
TNFα-FITC BD Pharmingen 6401.111 1:25 
 
Notes:  
All are murine monoclonals unless stated 
NA = not available for purchase 
All amplification/ detection antibodies are from Molecular Probes unless stated 
CD11c conjugated to A488 gives high non-specific epidermal staining. This was used where 
there were two IgG1 antibodies. 
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Table 2: Antibodies used for flow cytometry 
 
 
Antigen-fluorphor Manufacturer Clone Iso Dil 
BDCA-1 (CD1c)-FITC or PE Miltenyi AD5-8E7 IgG2a 1:50 
CD11c-PE-Cy7 BD Pharmingen B-ly6 IgG1 1:33 
CD163-A647 Acris 5C6-FAT IgG1 1:33 
Factor XIIIA-A647 Enzyme Research AP Polyclonal 
Sheep 
NA  1:33 
HLA-DR-APC-Cy7 BD L243 IgG2a 1:50 
CD14- PerCP Cy5.5 BD Pharmingen M5E2 IgG2a 1:25 
Lin-FITC BD various IgG1 & IgG2b 1:20 
CD1a-FITC Pharmingen HI149 IgG1 1:20 
CD40-FITC BD Pharmingen SC3 IgG1 1:20 
CD80-FITC BD Pharmingen L307.4 IgG1 1:20 
CD86-FITC BD Pharmingen 23GI (FUN-1) IgG1 1:20 
DEC-205 CD205)-PE BioLegend MG38 IgG2b 1:20 
MMR (CD206)-FITC BD Pharmingen HI 149 IgG1 1:20 
Langerin (CD207)-PE Immunotech DCGM4 IgG1 1:20 
DC-LAMP (CD208)-PE Immunotech 104.G4 IgG1 1:20 
DC-SIGN (CD209)-FITC BD Pharmingen DCN46 IgG2b 1:20 
BDCA-2-FITC Miltenyi AC144 IgG1 1:50 
CD45-FITC BD Pharmingen 2DI IgG1 1:20 
BDCA-3 – PE or FITC Miltenyi AD5-14H12 IgG1 1:50 
CD163-FITC Acris 5C6-FAT IgG1 1:20 
HLA-DR-Alexa 700 BioLegend L243 IgG2a 1:50 
CD16-PE-Cy7 BD Pharmingen 3G8 IgG1 1:33 
Lin-PE: CD3, CD19, CD20, 
CD56 
 Lab custom various IgG1 & IgG2b 1:20 
CD3-APC-Alexa 750 or Pacific 
Blue 
eBioscience OKT3 IgG2a 1:33 
CD4-PE-Cy7 eBioscience RPA-T4 IgG1 1:33 
CD8-PerCP-Cy5.5 BD Pharmingen SK1 IgG1 1:20 
IL-17- Alexa 488 eBioscience eBio64DEC17 rat IgG2a 1:20 
IFNγ - Alexa 700 BD Pharmingen B27 IgG1 1:33 
Live-Dead – aqua marina Invitrogen NA NA 1:100 
 
Notes:  
All are murine monoclonals unless stated 
NA = not available for purchase 
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CHAPTER 3: Characterization of DC subsets in normal human dermal skin  
 
DCs are a major resident leukocyte population in human skin. Two main types of 
DCs are found in non-inflamed skin: epidermal Langerhans cells (LC) and dermal DCs 
(Jenny Valladeau, 2005; Larregina and Falo, 2005). LC express Langerin/CD207, an 
endocytic receptor that localizes to and forms Birbeck granules, as well as the CD1a class 
I-like molecule that presents glycolipids (Hunger et al., 2004). Dermal DCs have long 
been defined on the basis of expression of a clotting factor, the transglutaminase, factor 
XIIIA (FXIIIA) (Cerio et al., 1989). Studies that define dermal DCs as FXIIIA+ have 
often relied on FACS analysis and functional studies using bulk tissue or enzymatically 
manipulated émigrés that “crawl out” of the dermis over a variable incubation period, 
which may increase FXIIIA expression (D. Torocsik, 2005; Per Henriksson, 1985). 
 
Currently, so-called myeloid or conventional DCs in many tissues are often 
identified on the basis of high expression of HLA-DR antigen presenting molecules and 
the CD11c integrin. DCs are Lin negative, where Lin is a cocktail of antibodies to other 
cell lineages, including T cells (CD3), B-cells (CD19 and CD20), monocytes (CD14), 
granulocytes and NK cells (CD16 and CD56) (Freudenthal and Steinman, 1990; 
Summers et al., 2001). Circulating myeloid DCs can be further classified as three 
mutually exclusive subsets: blood dendritic cell antigen (BDCA-1)+, CD16+, and BDCA-
3+ (in order of immunostimulatory capacity) (MacDonald et al., 2002), but these markers 
have seen very little use in studies of the skin.  
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Since a large number of prevalent dermatologic conditions from atopic dermatitis 
to psoriasis are characterized by extensive dermal T cell infiltration, and as DCs are 
pivotal antigen presenting cells for T cells, it is important to pursue these distinct 
phenotypic definitions of DCs in normal skin and peripheral blood. Here we report that 
CD11c and FXIIIA marked mutually exclusive populations, the former co-expressing 
BDCA-1, while FXIIIA+ cells were uniformly positively for CD163, a scavenger receptor 
for hemoglobin/ haptoglobin complexes. CD11c+ cells were more typical of DCs with 
higher HLA-DR expression and T cell stimulating activity. Surprisingly FXIIIA+ cells 
behaved more like macrophages since they were weak initiators of T cell responses in the 
mixed leukocyte reaction (MLR) and had numerous phagocytosed pigment-containing 
vacuoles in a tattoo. 
 
        
Characterization of dendritic cells in normal human skin and peripheral blood 
          
FXIIIA+ and CD11c+ cells are discrete dermal populations.  
Immunohistochemistry of normal human dermis showed distinct staining patterns 
for FXIIIA+ and CD11c+ cells (Figure 1A). The larger FXIIIA+ cells were located 
throughout the dermis. In contrast, CD11c+ myeloid cells were located in the papillary 
and upper reticular dermis. We counted the absolute number of FXIIIA+ and CD11c+ 
cells using matched tissue sections from 15 normal volunteers (Figure 1B). In the 
epidermis there were no FXIIIA+ cells and a mean of 4 CD11c+ cells (p=0.04) per mm. In 
the dermis, there was a mean of 83 FXIIIA+ cells compared to 61 CD11c+ cells per mm 
(p=0.19). Double-labeled immunofluorescence using FXIIIA (red) and CD11c (green) 
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confirmed that these two antigens were not expressed on the same cell (Figure 1C). A 
polyclonal FXIIIA antibody has typically been used for staining skin dermal DCs in the 
past. We used FXIIIA affinity purified sheep antibody for all of our double label 
immunofluorescence studies, as it gave the best staining in our hands. There was 100% 
co-expression of the sheep FXIIIA antibody and a commonly used mouse monoclonal 
(clone AC-1A1), while other mouse monoclonal antibodies to FXIIIA produced weaker 
and less consistent staining (data not shown). These data indicate that two commonly 
used markers for dermal DCs are actually expressed by comparably abundant but 
different populations.  
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Figure 1. Two antigens used to define normal dermal DCs (FXIIA and CD11c) are 
expressed on non-overlapping populations in situ. (A) Immunohistochemistry on normal 
human skin using FXIIIA (left panel) and CD11c (right panel) antibodies (n=15). 
FXIIIA+ cells were spread throughout the dermis, while CD11c+ cells were mainly 
localized to the superficial dermis. (B) There were similar numbers of CD11c+ and 
FXIIIA+ cells per mm in normal dermis. Standard error of the mean indicated. (C) 
FXIIIA and CD11c identified two discrete populations. Size bar = 100 µm.  
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FXIIIA+ and CD11c+ populations are not Langerhans cells (LC) or plasmacytoid DCs 
(PDCs).  
To further characterize these two dermal cell populations, we first assessed 
expression of markers used to identify LCs and PDCs, each applied in combination with 
antibodies to either FXIIIA or CD11c antibody. Neither FXIIIA nor CD11c co-localized 
with the LC marker CD1a (Figure 2A, B), nor the PDC marker CD123 (Figure 2C, D).  
Therefore FXIIIA+ and CD11c+ cells are distinct from additional LC and PDC 
populations in normal skin.
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Figure 2. FXIIIA+ and CD11c+ populations are not Langerhans cells or plasmacytoid 
DCs. Neither FXIIIA nor CD11c showed co-expression with Langerhans antigen CD1a 
(A, B), plasmacytoid antigen CD123 (C, D), or folicular DC anigen (E,F). Size bar = 
100µm. 
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CD11c+ cells co-express the blood DC marker BDCA-1/CD1c, and a small fraction 
also express DC-LAMP/CD208 and DEC-205/CD205.  
              BDCA-1 also marks a population of CD11c+ myeloid DCs in blood, and we 
noted co-expression of these two markers in the dermis as well (Figure 3A,B). Two 
other markers that are expressed by tissue DCs are a lysosomal marker, DC-lysosomal-
associated membrane protein (DC-LAMP)/CD208, and an endocytic receptor DEC-
205/CD205. A small fraction of the CD11c+ cells expressed these two markers (Figure 
3 C-F). The fraction of CD11c+/DC-LAMP+ cells is qualitatively much smaller than the 
fraction of CD11c+/DEC-205+ cells. DC-LAMP/CD208 is expressed during DC 
maturation, and we noted that cells positive for this marker were often in dermal 
aggregates with other DC-LAMP/CD208- CD11c+ cells. These results indicate that 
CD11c+ cells in the dermis share features with the myeloid DCs in blood, but some are 
in a more mature state of differentiation (Granelli-Piperno et al., 2005).  
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Figure 3. CD11c+ cells are defined by BDCA-1, DC-LAMP/CD208, and DEC-
205/CD205. FXIIIA did not overlap with BDCA-1 (A), DC-LAMP/CD208 (C), or DEC-
205/CD205 (E). Most CD11c+ cells co-expressed BDCA-1 (B). Small subsets of CD11c+ 
cells co-expressed DC-LAMP/CD208 (D), and DEC-205/CD205 (F). Size bar = 100µm. 
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FXIIIA+ cells express the macrophage marker and scavenger receptor, CD163.  
              CD163, a hemoglobin haptoglobin scavenger receptor identifies tissue resident 
macrophages, and it was the only marker we studied that was uniformly co-expressed 
by FXIIIA+ cells and not by CD11c+ cells (Figure 4A, B). Several other markers were 
expressed on a fraction of FXIIIA+ and CD11c+ cells. These included the uptake 
receptors macrophage mannose receptor (MMR)/CD206 (Figure 4C, D), dendritic cell-
specific ICAM-3-grabbing nonintegrin (DC-SIGN)/CD209 (Figure 4E, F), CD45, and 
HLA-DR (Figure 5). In normal skin, both MMR/CD206 and DC-SIGN/CD209 were 
more abundant on macrophages (FXIIIA+ cells) than DCs (CD11c+ cells), which is 
consistent with recent studies in inflamed skin and lymph node (Granelli-Piperno et al., 
2005; Krutzik et al., 2005). Reciprocally, CD45 and HLA-DR were more abundant on 
CD11c+ compared to FXIIIA+ cells. All these observations are consistent with the 
interpretation that CD11c+ cells in the dermis are part of the DC pathway of 
differentiation, while FXIIIA+ cells are more macrophage-like. 
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Figure 4. The macrophage marker CD163 defines FXIIIA+ cells. FXIIIA+ cells 
expressed macrophage marker CD163 (A), and a subset overlapped with MMR/CD206 
(MMR) (C) and DC-SIGN/CD209 (E). CD11c did not overlap with CD163 (B), but a 
subset overlapped with MMR/CD206 (D), and DC-SIGN/CD209 (F). Size bar = 
100µm. 
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Figure 5. HLA-DR and CD45 mark both CD11c+ and FXIIIA+ cells. FXIIIA+ cells had a 
lower expression level of CD45 (A) than CD11c+ cells (B). HLA-DR was also expressed 
to a lower extent on FXIIIA+ cells (C) than on CD11c+ cells (D). Size bar = 100µm. 
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Other markers of potential interest.  
Other markers used for characterization of FXIIIA and CD11c cells were CD14 
(identifies monocytes), CD68, CD11b, and RFD7 (commonly used macrophage markers) 
and CD63 (present on macrophages and DCs). These markers were not helpful in 
discriminating these two populations in normal skin (Figure 6). CD14, a component of 
the LPS receptor on monocytes (Gordon et al., 2005), was present on a few FXIIIA+ cells 
and CD11c+ cells. We have previously shown that CD68 identifies a subset of CD11c+ 
cells that produce IL-20 in psoriasis (Wang et al., 2006), so this is not an exclusive 
macrophage marker. In keeping with this, CD68 also stained both CD11c+ and FXIIIA+ 
cells. CD11b and RFD7, considered to be common macrophage markers (Gordon et al., 
2005; Tormey et al., 1997), were both present on both CD11c and FXIIIA cells. CD63, 
an MHC Class II internalization antigen, marked occasional CD11c+ and FXIIIA+ cells in 
normal skin.
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Figure 6. Other potential macrophage markers stained both FXIIIA+ and CD11c+ cells. 
FXIIIA+ and CD11c+ cells showed variable co-expression with CD14 (A, B), CD68 (C, 
D), CD11b (E, F), RFD7 (G, H), and CD63 (I, J). 
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Isolated CD11c+ dermal cells contain non-overlapping major and minor populations of 
BDCA-1+ and BDCA-3+ cells.  
To confirm our in situ data and assess whether or not the three myeloid DC 
subsets found in blood were also found in tissue, we performed 6-color FACS on single 
cell suspensions of normal human skin compared to peripheral blood, using a custom 
made group of mAbs to lineage (Lin) that did not contain mAbs to CD14 or CD16. 
Peripheral blood FACS dot-plots are shown in Figure 7A and B, and the parallel analysis 
from dermal cells is shown in Figure 7C and D.  There were three discrete Lin- CD11c+ 
HLA-DR+ DC populations in peripheral blood: BDCA-1+, CD16hi, and BDCA-3+ (Fig. 
7A), but only two clear populations in skin, BDCA-1+ CD16lo and BDCA-3+ CD16lo 
(Figure 7C). In blood, two discrete CD11c+ DC populations, BDCA-1+ and BDCA-3+ 
cells, were both DR+CD14- (Figure 7B). In contrast, BDCA-1+ cells from skin increased 
HLA-DR expression, and BDCA-3+ cells acquired low-level CD14 expression (Figure 
7D). We also confirmed that BDCA-1 and BDCA-3 identified discrete populations in 
normal skin in situ (data not shown). 
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Figure 7. Cutaneous DCs compared to blood DCs. (A) There were three non-overlapping 
DC populations in peripheral blood, gating on Lin-DR+CD11c+ cells: BDCA-1+, CD16hi, 
and BDCA-3+. (B) Blood BDCA-1+ (left) and BDCA-3+ (right) cells were both HLA-
DR+ CD14-. (C) In dermal single cell suspensions, BDCA-1+ cells acquired CD16. (D) 
BDCA-1+ (left) dermal cells increased HLA-DR expression, and BDCA-3+ (right) dermal 
cells acquired low-level CD14 expression. 
 53 
For FACS studies of isolated dermal cells, BDCA-1 and CD163 are superior markers to 
CD11c and FXIIIA respectively.  
To begin to test the functional properties of cell populations isolated from dermis, 
we required markers that would be optimal for FACS-sorting. While culture conditions 
may alter cellular surface phenotype, it was important to compare DC populations using 
the new BDCA-1 and CD163 markers with previous studies on dermal DCs. It was 
necessary to balance obtaining sufficient cells to study with as little manipulation as 
possible. An overnight culture in dispase/collagenase media (Angel et al., 2006) gave 
insufficient cells to perform our MLR experiments. Enzymatic alteration of surface 
epitopes is also possible, although experiments on PBMCs did not show loss of FACS 
staining after culture in dispase collagenase mix (unpublished data). This method was 
modified to allow 1-2 days of culture so any lost surface markers could be re-expressed, 
and allow DCs and macrophages to move out of the scored upper and lower dermal 
surfaces. Comparison of BDCA-1 versus CD163 on the first day of culture (after 
overnight culture in dispase/collagenase) and 24 and 48 hours culture showed a similar 
clear distinction of the two populations (data not shown). Culture of bulk dermal cells 
from normal skin (using this method) with and without DC maturation cytokines (IL-1β, 
IL-6, TNF and PGE2) showed that there was surprisingly little maturation of myeloid 
DCs (BDCA-1+) as measured by HLA-DR and CD83 (data not shown). 
We found that BDCA-1, which double labels > 90% of CD11c+ cells by in situ 
immunofluorescence (Figure 3B), had a much higher median fluorescence intensity 
(MFI) than CD11c (data not shown). Likewise, CD163, which showed 100% co-
expression with FXIIIA in situ (Figure 4A), proved to be a much better FACS marker 
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because FXIIIA antibodies bound non-specifically to dermal cells in suspension perhaps 
due to adherence of platelet fragments which are rich in FXIIIA (data not shown), and 
FXIIIA is upregulated during cell culture (D. Torocsik, 2005; Per Henriksson, 1985). 
Double label immunofluorescence of BDCA-1 and CD163 confirmed that they were 
distinct populations in situ (Figure 8A), and supported their use as alternative markers for 
CD11c and FXIIIA, respectively, in FACS studies.  
Bulk dermal single cell suspensions showed distinct BDCA-1+ (circled in red) and 
CD163hi (circled in blue) populations by FACS (Figure 8B). BDCA-1+ gated cells (red 
line) had a higher MFI for CD11c than the CD163hi population (blue line) compared to 
isotype (green line) (Figure 8C upper left), most likely due to increased sensitivity of 
FACS compared to immunohistochemistry. CD163hi cells had a higher MFI for FXIIIA 
than BDCA-1+ cells (Figure 8C upper right). BDCA-1+ gated cells also had a higher MFI 
for HLA-DR and CD45 than CD163 hi gated cells (Figure 8C lower left and right). A 
subset of BDCA-1+ cells was positive for DC maturation markers CD86, CD83, and DC-
LAMP/CD208 (Figure 8D). As B cells may also express BDCA-1, we confirmed that 
none of the BDCA-1+ cells were CD19+ by FACS (data not shown). Thus the dermal 
cells have a pattern of expression similar to in situ characterization.  
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Figure 8. BDCA-1 and CD163 are alternative markers for CD11c and FXIIIA 
respectively. (A) BDCA-1 and CD163 identified discrete populations of dermal cells. (B) 
BDCA-1+ cells (red circle) and CD163+ cells (blue circle) were also discrete populations 
in dermal single cell suspensions. (C) FACS histograms gated on BDCA-1+ cells (red 
line), CD163+ cells (blue line), or isotype (green line). BDCA-1+ were CD11chi, 
FXIIIAlo, HLA-DRhi, and CD45hi. CD163+ cells were CD11cmid, FXIIIAhi, HLA-DRmid, 
and CD45lo. (D) A subset of BDCA-1+ cells was CD86hi, CD83+, and DC-LAMP hi. 
Representative graphs from 3 experiments. Size bar = 100µm. 
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BDCA-1+ cells are a major immunostimulatory population from normal human skin.  
To test for the immunostimulatory properties of dermal leukocytes, we focused on 
FACS-sorted populations of BDCA-1+ and CD163 hi cells released from the dermis with 
collagenase. Figure 9 shows a representative FACS plot of the MLR. The post-sorted 
cells (red) were 99% pure compared to isotype (blue) (Figure 9A). In the MLR induced 
by in vitro monocyte-derived mature DCs, 63% of the surviving T cells had undergone 
extensive proliferation at a ratio of stimulators to responders of 1:100 on day 8 post-sort 
(Figure 9B). In parallel cultures stimulated by BDCA-1+ cells, 9.1% of the T cells had 
proliferated (1:10), compared to CD163+ cells (2.1%), and background T cell 
proliferation (1.0%) (Figure 9C). When these sorted BDCA-1+ and CD163+ populations 
were cultured for 2 days in a DC-maturing cytokine cocktail before setting up the MLR, 
the immunostimulatory capability of BDCA-1+ cells was increased to 25.2% (1:100) but 
the capacity of CD163+ cells was unchanged (2.2%; 1:250, low ratio due to low cell 
survival during 2 day culture period) (Figure 9C). BDCA-1+ sorted cells cultured for 2 
days without cytokines, and the supernatant from these cells after culture, also increased 
T cell proliferation (data not shown). 
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Figure 9. BDCA-1+ cells are more immunostimulatory. (A) Post-sort dot-plot of dermal 
cells from normal skin into BDCA-1+ population (red, upper left panel), and CD163+ 
population (red, upper right panel) compared to isotype (blue). (B) Positive control 
(monocyte-derived mature DC) for MLR on day 8 post sort at 1:100 stimulator to 
responder ratio. Gate contains CD3+ proliferating T cells with left-shifted CFSE. (C) 
Using BDCA-1+ sorted cells as stimulators (1:10), 9.1% of the T cells proliferated; using 
CD163+ cells (1:10), 2.1% of live T cells proliferated. Background proliferation of T cells 
alone, without stimulation was 1.0%. After cells had been sorted and cultured for 2 days 
with cytokines to induce maturation, there was a marked increase in the T cell 
stimulatory capacity of BDCA-1+ cells (25.2%, 1:100) versus CD163 (2.2%, 1:250). 
Representative graphs from 3 experiments. 
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CD163+ cells phagocytose large particles in a tattoo and have the structural features of 
macrophages.  
Ultra-thin sections of a green-dye-tattoo were cut from tattoo-bearing normal 
skin. These sections confirmed that the dye was intracytoplasmic, and mostly located in 
cells clustered around blood vessels (Figure 10A). Electron microscopy of the tattoo 
revealed membrane-bound (Figure 10B, blue arrow) tattoo dye particles (red arrow), and 
microvillus projections (green arrow) confirming the identity of these cells as 
macrophages. Immunohistochemistry using BDCA-1 (Figure 10C) or CD163 (Figure 
10D) showed that dye laden cells were CD163+ and not BDCA-1+, confirming that 
typical macrophages rather than DCs had ingested the pigment. 
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Figure 10. CD163+ cells phagocytose large particles and have the structural features of 
macrophages. (A) Tattoo skin section (0.5µm) stained with toluidine blue. Cells 
containing green tattoo dye in their cytoplasm (black arrow) surrounded a blood vessel. 
(B) Electron microscopy of a tattoo showed that dye particles (red arrow) were 
membrane bound (blue arrow) within the cytoplasm of a cell with multiple microvillus 
protrusions (green arrow). (C, D) Cells containing green tattoo dye particles stained for 
CD163 but not BDCA-1. Size bar = 10µm (A, C, D) and 200nm (B). 
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Discussion 
DCs are important sentinels of the cutaneous immune system, performing central 
roles in both the innate and acquired immune system. Previous characterization of DC 
subsets in human dermis has been influenced by results with a rabbit polyclonal antibody 
to FXIIIA, which identifies dermal cells with a dendritic morphology (Cerio et al., 1989; 
Deguchi et al., 2002; Frank O. Nestle, 1993; Meunier et al., 1993; Nestle et al., 1994). 
Here we have characterized populations of cells within the normal dermis and find 
surprisingly that cells expressing the CD11c integrin and the BDCA-1/CD1c antigen 
presenting molecule are a distinct population that are functionally differentiated along the 
DC pathway, whereas FXIIIA+ cells are differentiated along the macrophage pathway. 
Whereas mouse skin contains approximately one CD11c+ DC for every five macrophages 
(Dupasquier et al., 2004), the concentration of CD11c+ DCs in human skin is much 
higher, and is closer to a 1:1 ratio. 
 
CD11c+ co-localized with several well-recognized DC markers: BDCA-1, DC-
LAMP/CD208, and DEC-205/CD205. BDCA-1, also known as CD1c (Brenner, 2004), is 
an invariant MHC Class I-like antigen receptor molecule that recognizes lipids in 
mycobacterial cell walls. BDCA-1 is found on immature and mature DCs, and also on a 
subset of B Cells. BDCA-1, in the absence of the B cell markers CD19 and CD20, would 
therefore seem like a valuable marker to compare dermal DCs in both normal skin 
(Narbutt et al., 2006) and inflammatory skin diseases (David P. Fivenson, 1995). DC-
LAMP/CD208 is a lysosomal protein that specifically marks mature DCs (de Saint-Vis et 
al., 1998). DEC-205/CD205 is a surface receptor that participates in DC antigen 
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endocytosis; its expression increases during maturation, and it has been previously 
demonstrated in normal human skin (Ebner et al., 2004). A low frequency of CD11c+ 
DCs expressing these two antigens in normal skin is consistent with their expected 
immature DC status. CD11c+ cells also stain brightly with HLA-DR and CD45, 
confirming their antigen presenting potential and bone marrow origin, respectively. The 
phenotype of BDCA-1+ cells from skin indicates that they are all CD45hi/HLA-DRhi and 
a subset are CD86+ and CD83+. 
 
Our studies show that FXIIIA identifies a population of tissue-resident 
macrophages in normal skin. The only antibody that overlapped completely with FXIIIA 
in situ was the scavenger receptor CD163, which is selectively expressed on monocytes 
and macrophages, reviewed in (Fabriek et al., 2005). The best characterized function of 
CD163 is to bind hemoglobin/ haptoglobin complexes, which may be important in 
homeostasis. There was low-level CD45 and HLA-DR expression, consistent with other 
tissue macrophages, and limited antigen-presenting capacity (Janeway et al., 2001). 
MMR/CD206 and DC-SIGN/CD209 are C-type lectin receptors that are found on both 
macrophages and DCs (Granelli-Piperno et al., 2005; McGreal et al., 2005), so it was not 
surprising that there was expression of both lectin receptors on both FXIIIA+ and CD11c+ 
cells in normal human skin.  
 
To evaluate the function of these two dominant dermal populations, we used two 
approaches. By comparing BDCA-1 and CD163 cells selected from collagenase digests 
of normal skin as inducers of an allogeneic MLR, we found that BDCA-1+ cells were the 
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main immunostimulatory population. These BDCA-1+ cells could induce increased T cell 
proliferation when cultured before setting up the MLR, but were not as 
immunostimulatory as in vitro matured DCs, suggesting that there were few mature DCs 
in normal skin compared to those found in inflammatory conditions such as psoriasis. 
This result reflects studies by Nestle et al. showing that bulk tissue émigrés from normal 
skin are not as stimulatory as those from psoriasis patients (Nestle et al., 1994). In 
comparison, CD163hi cells were not immunostimulatory in an allo-MLR, nor could they 
be induced to be stimulatory, although they may possess some antigen presenting 
capacity with up-regulation of class II MHC molecules (Steinman, 2006). 
 
Skin tattoos provided a second functional study- the phagocytic activity of tissue 
macrophages. Pigment granules were found in lysosomal-like cellular structures, and 
cells containing pigment stained uniformly with CD163. The fate of tattoo pigment 
injected into dermal tissues has been studied in the past, and fibroblasts were considered 
to be the primary long-term reservoir of the pigment granules, with pigment in occasional 
macrophages (Fujita et al., 1988; Lea and Pawlowski, 1987). However, our data suggest 
that macrophages are indeed a significant store of the dermal pigment. The cells with 
pigment were CD163+ and BDCA-1-, round, had numerous microvillous projections, and 
the pigment is contained within membrane bound structures. These characteristics are 
consistent with macrophages (Demidem et al., 1991; Fujita et al., 1988).  
 
In summary, we have identified CD11c+ cells as immature myeloid DCs in 
normal human skin, and FXIIIA+ cells as tissue-resident macrophages, not DCs as they 
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were previously classified. In future studies of cutaneous DCs, we would recommend 
considering the use of CD11c/BDCA-1 and CD163 as alternative markers to identify 
dermal DCs and macrophages, respectively, as they are more specific and more useful in 
flow cytometry applications.  
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CHAPTER 4: Characterization of DC subsets in inflamed human dermal skin  
 
Psoriasis is a common chronic inflammatory skin disease, which results in great 
morbidity for severely affected patients. In recent years much progress has been made 
understanding the pathogenesis and treatment of this disease. We now appreciate that 
psoriasis results from complex interactions between T cells, dendritic cells (DCs), and 
keratinocytes (Lowes et al., 2007).  Until recently, psoriasis has been considered a 
classical Type 1 autoimmune disease, with a strong IFNγ Th1 signal. However, a new 
subset of T cells, Th17 cells, have now been described in murine models of autoimmune 
inflammation (Weaver et al., 2007), and we have reported the presence of these cells in 
psoriasis (Lowes et al., 2008). Th17 cells produce IL-17, IL-22, and have other important 
downstream pro-inflammatory effects in skin (Liang et al., 2006; Zheng et al., 2007). 
DCs may be very central pathogenic players in psoriasis, both by activating T cells and 
by producing amplifying cytokines and chemokines during inflammation. In the skin the 
main DC populations include epidermal DCs (Langerhans cells) and dermal DCs 
(myeloid DCs and plasmacytoid DCs). We were interested in further characterizing 
dermal myeloid DCs in psoriasis, as these cells may be an important therapeutic target.  
 
Recently, we described that the best marker for identifying dermal myeloid DCs 
in normal skin is CD11c (Zaba et al., 2007b). Also, we have previously reported that 
there is a large increase in CD11c+ cells in psoriasis (Abrams et al., 1999; Gottlieb et al., 
2005; Lowes et al., 2005a)}. These CD11c+ cells include a subset of inflammatory DCs 
called TNF- and inducible nitric oxide synthase (iNOS) -producing DCs, or Tip-DCs 
(Lowes et al., 2005a). Tip-DCs were first described in the spleen during a murine model 
 65 
of Listeria monocytogenes infection (Serbina et al., 2003; Tam and Wick, 2004). 
Pathogenicity of these Tip-DCs in psoriasis is suggested by the rapid downmodulation of 
Tip-DC products TNF, iNOS, IL-20, and IL-23 during effective treatment with TNF 
blocking drugs (Zaba et al., 2007a).   
 
In normal skin, CD11c+ cells are nearly all blood dendritic cell antigen (BDCA)-
1+. BDCA-1 is also known as CD1c, and this molecule is part of the CD1 family of 
invariant MHC molecules that are important in presentation of lipid antigens to T cells 
(Barral and Brenner, 2007).  In this manuscript, we show that unlike normal skin, most of 
these CD11c+ cells in psoriatic plaques are actually BDCA-1-. They are relatively 
immature DCs, as they do not express DC-LAMP (dendritic cell -lysosomal-membrane 
associated protein) and DEC-205/CD205. Hence, in situ there were two main types of 
dermal DCs in psoriasis lesions:  CD11c+BDCA-1+ resident DCs, and CD11c+BDCA-1- 
inflammatory DCs. Dermal single cell suspensions for phenotype analysis and functional 
studies showed that both populations were allo-stimulatory and were able to polarize 
allogeneic T cells into IL-17 producing Th17 cells.      
   
 
Characterization of dendritic cells in psoriatic lesional skin and peripheral blood 
Psoriatic myeloid dermal DCs are CD11c+BDCA-1-BDCA-3-.   
To quantify cells in each dermal DC compartment, we performed 
immunohistochemistry on normal skin and psoriasis paired lesional/ non-lesional samples 
(n=20) (Figure 11).  Both non-lesional and lesional psoriasis samples had 5-fold fewer 
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BDCA-1+ DCs (Figure 11A) (p<0.001). However, BDCA-1 cell counts did not change 
significantly in a group of psoriatic patients treated with etanercept (Figure 11C) (Zaba et 
al., 2007a). There were 2-fold more BDCA-3+ DCs compared to normal skin (p<0.001 
and p<0.05, respectively) (Figure 11B). CD11c+BDCA-1-BDCA-3- cell numbers were 
calculated by subtracting BDCA-1 and BDCA-3 cell counts from CD11c cell counts. 
While lesional and non-lesional psoriasis sections contained similar numbers of BDCA-
1+ and BDCA-3+ cells, CD11c+BDCA-1-BDCA-3- cells were increased 10-fold in 
psoriasis plaques compared to non-lesional skin (p<0.001), and 30-fold compared to 
normal skin (Figure 11C) (p<0.001). In addition, we performed FACS on whole blood 
from normal (n=6) and psoriasis (n=6) subjects, and found that all three previously 
defined myeloid DC subsets (MacDonald et al., 2002) were decreased in peripheral blood 
of psoriasis patients compared to normal volunteers (Figure 11D, E).  
We next evaluated these populations in situ by 2 color immunofluorescence. In 
previous studies on normal human skin, we have characterized two populations of 
myeloid CD11c+ dermal DCs: BDCA-1+ dermal DCs comprise approximately 90% of all 
CD11c+ dermal cells, and the remaining 10% of CD11c+ cells are BDCA-1- (Zaba et al., 
2007b).  We found that in psoriasis, there was a reversal of this ratio of BDCA-1+ cells, 
as the minority of the CD11c+ cells co-expressed BDCA-1 (Figure 12A). BDCA-1+ cells 
were aggregated together in dermal clumps (Figure 12A, 2B), compared to CD11c+ cells, 
which were located mostly in the upper reticular dermis and dermal papillae. BDCA-3 
identifies an additional population of myeloid DCs in the circulation (MacDonald et al., 
2002) and in psoriatic dermis (Figure 12B).  This marker was expressed on CD11c+ cells 
scattered throughout the dermis and also on blood vessels (Figure 11C). As 
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CD11c+BDCA-1+ cells are the major resident dermal DC population in normal skin, the 
remainder of our study compares resident CD11c+BDCA-1+ DCs with CD11c+BDCA-1- 
DCs in the psoriatic inflammatory infiltrate. 
 68 
Figure 11 . CD11c+ dermal DCs are the major DC population accumulating in psoriasis 
lesional skin and psoriasis peripheral blood contains fewer DCs than normal controls. 
(A) Representative immunohistochemistry of BDCA-1+ cells, BDCA-3+ cells, and 
CD11c+ cells in normal, non-lesional and lesional psoriatic skin. (B) Quantification of 
myeloid DCs per mm skin stained by immunohistochemistry of normal skin (red boxes; 
n=20), non-lesional skin (light blue boxes; n=20), and matched psoriatic lesional skin 
(dark blue boxes; n=20).  CD11c+BDCA-1-BDCA-3- cell numbers were calculated by 
subtracting BDCA-1 and BDCA-3 cell counts from CD11c cell counts. FACS analysis of 
150µL peripheral blood from normal volunteers (n=6) and psoriasis patients (n=6).  Cells 
were gated on CD3-CD14-CD56-CD14-DR+11c+. (A) BDCA-1 cell counts during a 
clinical trial with etanercept, showing stable cell counts throughout the treatment period. 
(B) Representative FACS plots comparing circulating BDCA-1+ and BDCA-3+ cells in 
normal and psoriatic circulation. (C) Quantification of all patients showing a reduction in 
the circulation of BDCA-1+ and BDCA-3+ populations in psoriasis (blue) compared to 
normal patients (red). Error bars indicate SEM.  p<0.05 (*), p<0.01 (**), p<0.001 (***).  
Size bar = 100µm. 
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Figure 12 . Most CD11c+ myeloid DCs are BDCA-1- in psoriasis lesional skin. (A) The 
majority of CD11c+ cells in psoriatic dermis were BDCA-1-, while a small subset of 
CD11c+ cells co-expressed BDCA-1+. (B) BDCA-1 and BDCA-3 identified separate 
myeloid DC populations in the dermis. (C) Most BDCA-3+ cells co-expressed CD11c, 
and some BDCA-3 staining was observed on blood vessels. In all IF figures, single 
stained controls are above the merged image, white line denotes dermo-epidermal 
junction, dermal collagen fibers gave green autofluorescence, and antibodies conjugated 
with a fluorochrome often gave background epidermal fluorescence. Size bar = 100µm. 
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CD11c+ BDCA-1- myeloid dermal DCs include TNF-and-iNOS producing dendritic cell 
(Tip-DCs) population.    
In psoriasis lesional tissue, the majority of CD11c+ cells were iNOS producing 
(Figure 13A), and the cellular iNOS expression appeared punctate and intracytoplasmic. 
Resident CD11c+ BDCA-1+ dermal DCs had <10% iNOS co-expression (Figure 13B). 
Similarly, TNF was expressed by >90% of CD11c+ cells (Figure 13C) and <20% of 
CD11c+ BDCA-1+ dermal DCs  (Figure 13D). In addition, iNOS and TNF identified 
occasional  non-lesional Tip-DCs (Figure 13E) and many lesional Tip-DCs (Figure 13F), 
and all cells strongly expressing iNOS also expressed TNF. In conclusion, Tip-DCs were 
found in the CD11c+ BDCA-1- myeloid DC population. 
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Figure 13 . CD11c+BDCA-1- DCs contain the Tip-DC population. (A) Most CD11c+ 
dermal DCs in psoriatic lesional skin co-expressed iNOS compared to (B) BDCA-1+ 
cells. (C) Most CD11c+ dermal DCs in lesional psoriatic skin co-expressed TNF 
compared to (D) BDCA-1+ cells. Approximately 25% of BDCA-1+ cells co-expressed 
TNF. (E,F) iNOS and TNF were co-expressed in the same cell, identifying Tip-DCs in 
situ. Few Tip-DCs were observed in (E) psoriatic non-lesional skin compared to lesional 
skin (F). Size bar = 100µm. 
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CD11c+ BDCA-1- inflammatory DCs show some expression of macrophage markers 
compared to BDCA-1+ cells. 
 In order to further characterize the CD11c+ myeloid DCs, we evaluated co-
expression with a series of myeloid cell markers (Figures 14, 15). Over half of CD11c+ 
DCs expressed low level CD14 (Figure 14A). Most CD11c+ cells in the papillary dermis 
were CD14-, while most in the reticular dermis were CD14lo.  In contrast, only occasional 
BDCA-1+ cells expressed CD14 (Figure 14B). DC-SIGN/CD209, a marker of both 
immature DCs and macrophages in normal human skin (Zaba et al., 2007b), partially co-
localized with CD11c (Figure 14C) but did not co-localize with BDCA-1 (Figure 14D).  
Similarly, CD163, a marker of normal dermal macrophages (Zaba et al., 2007b), blood 
monocytes, and blood DCs (Maniecki et al., 2006), was expressed on some CD11c+ cells 
(Figure 14E), but not on CD11c+BDCA-1+ DCs.  In normal skin, CD11c is not expressed 
on CD163+ macrophages (Zaba et al., 2007b), despite the myeloid origin of 
macrophages.  
 Single antigens specific for mature DCs include endocytic receptor DEC-
205/CD205 and DC-LAMP/ CD208 (Figure 15). Nearly all DC-LAMP+ and DEC-205+ 
cells were in dermal aggregates, and co-expressed CD11c+ and BDCA-1+. While nearly 
all BDCA-1+ cells co-expressed these two mature DC markers, there were many CD11c+ 
cells that did not, identifying a less mature population of BDCA-1- myeloid dermal DCs. 
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Figure 14.  CD11c+BDCA-1- inflammatory dermal DCs express CD14 and DC-SIGN. 
(A) A subset of CD11c+ cells in the reticular dermis expressed low level CD14.  (B) Few 
BDCA-1+ dermal DCs co-expressed CD14, and (C) 80% of CD11c+ cells were DC-
SIGN+. This was not an exclusive myeloid DC marker as some DC-SIGN+ cells were not 
CD11c+. (D) BDCA-1+ cells did not co-express DC-SIGN. (E) CD163+ macrophages 
showed some CD11c co-expression. (F) BDCA-1+ cells did not express CD163. Size bar 
= 100µm. 
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Figure 15.  CD11c+BDCA-1+ cells are phenotypically mature dermal DCs in psoriasis. 
DC-LAMP and DEC-205 identified mature DCs, often located in dermal aggregates. (A) 
DC-LAMP+ cells were CD11c+, and (B) BDCA-1+. (C) DEC-205+ cells were CD11c+, 
and (D) BDCA-1+. There were many CD11c+ cells that were not positive for these two 
markers in the psoriatic dermis. Size bar = 100µm. 
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Myeloid DCs obtained from psoriatic dermis are immunostimulatory and activate Th17 
and Th1 cells.  
Single cell suspensions of normal skin (n=3) and psoriasis lesions (n=3) were 
obtained by enzymatic splitting of the epidermis, and then culturing the dermis for 2-3 
days to allow the leukocytes to migrate out of the dermal scaffold. For functional 
experiments, we then FACS-sorted this bulk dermal single cell suspension, obtaining 
10,000-50,000 cells in each population.  
 
(a) Surface phenotype. For surface phenotyping of normal and psoriatic dermal 
myeloid DCs by FACS, large cells were gated on CD11c+HLA-DR+, a classic definition 
of a myeloid DC, and further gated according to BDCA-1 expression (Figure 16A). 
Expression levels of CD11c myeloid lineage marker, HLA-DR MHC-II protein, CD14 
LPS receptor, and CD16 FcγRIIIa were measured on BDCA-1+ resident DCs from 
normal dermis (Figure 16A, left, box 1), BDCA-1+ resident DCs from psoriatic dermis 
(Figure 16A, right, box 2), and BDCA-1- inflammatory DCs from psoriatic dermis 
(Figure 16A, right, box 3). CD11c+BDCA-1+ resident dermal DCs from both normal 
(Figure 16B, row 1) and psoriasis skin (Figure 16B, row 2) had similar levels of CD11c, 
HLA-DR, CD14, and CD16 expression and were similar in size (SSC-A) (isotype light 
gray fill). In contrast, CD11c+BDCA-1- psoriatic dermal DCs (Figure 16B, row 3) had 
10-fold decreased HLA-DR expression, 3-6 fold increased CD14 expression, and were 
20% smaller than both CD11c+ BDCA-1+ populations. Blood monocytes expressed 
similar levels of CD11c and HLA-DR as CD11c+ BDCA-1- psoriatic dermal DCs (data 
not shown), but were 99% CD14hi (Figure 16B, row 3, black line no fill) unlike CD11c+ 
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BDCA-1- psoriatic dermal DCs which were CD14mid. Expression of co-stimulatory 
molecules CD86 was highest on DC in psoriasis CD11c+ BDCA-1+ in psoriasis, and 
CD40 was low on all three populations. Thus, psoriatic CD11c+BDCA-1+ dermal DCs 
are phenotypically similar to normal resident CD11c+BDCA-1+ dermal DCs, whereas 
psoriatic CD11c+BDCA-1- cells share phenotypic features of both DCs and monocytes. 
 
(b) Allo-MLR. To test the immunostimulatory capacity of psoriatic dermal DC 
populations, we FACS-sorted DCs (CD11c+HLA-DRhiBDCA-1+ or CD11c+HLA-
DRhiBDCA-1-) and macrophages (CD163hi) for co-culture as stimulators in an allogeneic 
mixed leukocyte reactions (allo-MLR) (Figure 17A, right). Mature monocyte derived 
DCs (MoDCs) and T cells alone served as positive and negative controls, respectively.  
Figure 7 shows a representative experiment (n=3). 73.2% of living T cells stimulated 
with MoDCs at a stimulator/responder ratio of 1:50 on day 8 post sort had undergone 
extensive proliferation (Figure 17B).  MLRs without a stimulator population (T cells) 
alone had 2.5% background proliferation. CD163hi cells were not more 
immunostimulatory than T cells alone (2.3%), whereas both CD11c+BDCA-1+ resident 
DCs and CD11c+BDCA-1- inflammatory DCs were similarly immunostimulatory (55.3% 
and 64.5%, respectively).  Bulk psoriatic dermal single cell suspensions stimulate 60% 
(data not shown). These results suggest that CD163hi cells in psoriasis are non-
immunostimulatory macrophages expressing low level CD11c (Figure 14E), and that 
although CD11c+BDCA-1- are phenotypically less mature than the CD11c+BDCA-1+ 
cells, they are comparably immunostimulatory. 
 
 78 
 (c) Induction of intracellular cytokines in T cells. We recently demonstrated the 
presence of Th17 cells from the dermis of psoriatic plaques (Lowes et al., 2008).  We 
now show that CD11c+ BDCA-1+ and CD11c+ BDCA-1- psoriatic dermal DCs induce IL-
17 production in allogeneic CD4+ T cells.  Psoriatic dermal émigrés (n=3) were sorted as 
previously described into CD11c+ BDCA-1- DCs, CD11c+ BDCA-1+ DCs, or CD163+ 
macrophages and mixed with normal donor T cells at a 1:10 stimulator: responder ratio.  
Normal skin dermal émigrés (n=2) were sorted into BDCA-1+ and CD163+ populations. 
Cells were cultured for 9 days before analysis of T cell intracellular cytokines and IL-17 
and IFNγ cytokine production in the supernatant. Figure 18 shows a representative 
experiment. 
There were few T cells positive for IL-17 or IFNγ when the T cells were cultured 
alone (Figure 18A, left), with marked increases when cells were stimulated with 
CD3/CD28 beads (Figure 18A, right). Culture of the single cell suspensions alone, 
without addition of the allogeneic T cells, gave similar results to T cells alone, indicating 
the capability of the syngeneic T cells in the suspension (Figure 18B). There was marked 
increase in the intracellular cytokine staining when the dermal DCs were cultured with 
allogeneic T cells (Figure 18C), much more so for the psoriasis lesions. We particularly 
noted the increase of the IL-17+IFNγ+ cells induced by the psoriatic DCs, from 0.2% to 
12.1%. The psoriatic dermal single cell suspensions also induced more IL-17 and IFNγ 
protein than normal skin (Figure 18D).  This was similar to controls of T cells alone, and 
T cells stimulated with CD3/CD28 beads (data not shown). 
The psoriatic BDCA-1+ and BDCA-1- populations were able to induce similar 
percentages of these IL-17+IFNγ+ cells, although less than the bulk dermal single cell 
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suspensions (Figure 18E, 17F, right). This reduction is likely due to the process of FACS-
sorting, as sorting reduces the ability of the DCs to polarize T cells by an average of 6-
fold (analysis of the ability of bulk single cell suspensions before and after sorting, data 
not shown). The BDCA-1+ DCs from normal skin did not induce IL-17+ IFNγ+ cells 
(Figure 18E, left), nor did the normal or psoriatic skin macrophages (Figure 18G). There 
was low level of IL-17 and IFNγ cytokines in the supernatants, likely due to the lower 
cytokine expression in these cells (data not shown). 
In summary, normal skin dermal émigrés polarized few Th17 cells, none of which 
were IL-17- and IFNγ-producing, while psoriatic bulk émigrés and dermal DCs (BDCA-
1+ and BDCA-1-) polarized Th17 cells producing both IL-17 and IFNγ.  CD163+ 
macrophages from either normal or psoriatic skin were not able to polarize T cells to 
produce IL-17. 
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Figure 16.  Psoriatic inflammatory dermal DCs (CD11c+ BDCA-1-) are less mature than 
resident BDCA-1+ dermal DCs. Flow cytometric analysis of single cell suspensions of 
dermal émigrés from normal dermis or psoriatic dermis (n=3 for each). (A) Large cells 
gated on CD11c+ HLA-DRhi. In normal dermis, most myeloid DCs were BDCA-1+(box 
1). In psoriatic dermis, myeloid DCs were either BDCA-1+ (box 2), or BDCA-1- (box 3). 
(B) Histograms in each row were gated on boxes (1-3) as identified above in Figure 2a.  
Dark grey histogram represents antigen expression, light grey is isotype, and no fill (row 
3) is CD14 expression on blood monocytes.  MFI  indicated in the upper right or upper 
left corner of each histogram. Resident BDCA-1+ myeloid DCs from normal and 
psoriatic dermis were phenotypically similar, while the additional population of BDCA-1- 




Figure 17.  Both psoriatic CD11c+BDCA-1+ resident DCs and CD11c+BDCA-1- 
inflammatory DCs were immunostimulatory in an allo-MLR.  Single-cell suspensions of 
psoriatic dermal émigrés were sorted into (A, left) CD163hi or (A, right), CD3-
CD45+HLA-DRhiCD11chiBDCA-1+ or CD3-CD45+HLA-DRhiCD11chiBDCA-1- 
compared to isotype (red). (B) Gate contains CD3+ proliferating T cells with left-shifted 
CFSE as cells proliferated. Positive control (monocyte-derived mature DCs) on day 8-
post sort at 1:50 stimulator to responder ratio. Background proliferation of T cells alone 
(2.5%), CD163hi cells did not stimulate above background.  BDCA-1+ and BDCA-1- cells 
stimulated T cell proliferation similarly (both >55%). Representative graphs from 3 
experiments. 
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Figure 18.  Psoriatic dermal DCs induce IL-17/IFNγ producing T cells.  Allogeneic T 
cell responders were mixed with FACS-sorted stimulator populations described in Figure 
6, or with bulk émigrés from either normal or psoriatic dermal skin, at 1:10 ratio for 9 
days. Intracellular cytokine expression of T cells (live CD3+CD4+CD8- cells) measured 
by flow cytometry (A,B,C,E,F,G) or protein supernatant (D). (B,C,E,F,G) Comparison of 
T cell polarization of normal dermal DCs (left panels) with psoriatic dermal DCs (right 
panels). (A) Controls: T cells alone (left panel) demonstrated baseline intracellular 
cytokine expression and T cells + beads (right panel) measured intracellular cytokine 
expression following CD3/CD28 bead stimulation. (B) Bulk émigrés w/o responder T 
cells measured baseline T cell cytokine production in single cell suspensions. Other 
stimulator populations mixed with responder T cells were (C) unsorted bulk émigrés, (E) 
sorted HLA-DR+CD11c+BDCA-1+ dermal DCs, (F) sorted HLA-DR+CD11c+BDCA-1- 
dermal DCs, or (G) sorted CD163+ macrophages. Psoriatic bulk dermal DCs induced a 
population of IL-17/IFNγ producing T cells, as did BDCA-1+ and BDCA-1- DCs 
(although to a lesser degree, possibly due to sorting). Quadrant percentages are given, 
representative graphs from 3 experiments. (D) Supernatant of the same cultures was 
collected for analysis of cytokine protein expression Bulk psoriatic dermal émigrés mixed 






In psoriasis as well as normal skin, myeloid DCs identified by BDCA-1 were 
present, and their numbers remained the same during a course of etanercept therapy. 
These resident BDCA-1+ DCs were often in clumps in the dermis, and were positive for 
mature markers such as DC-LAMP and DEC-205. In psoriasis, there was a marked 
increase in CD11c+ cells currently best identified as BDCA-1-, and we have termed these 
BDCA-1- dermal cells “inflammatory” myeloid DCs. This group of inflammatory cells 
may be heterogeneous, including the Tip-DCs, IL-20-producing DCs (Wang et al., 2006), 
and possibly IL-23-producing DCs (Lee et al., 2004; Zaba et al., 2007a). The success of 
anti-TNF therapies to reduce all these cytokines and mediators and reverse the psoriatic 
phenotype supports the potential pathogenic role of these DCs (Zaba et al., 2007a). A 
similar finding was recently described in normal and diseased kidney, with a stable 
number of BDCA-1+ cells during inflammation (Woltman et al., 2007).  In this study, 
DC-SIGN was used as an alternative marker of DCs, and these cells did increase during 
rejection. 
 
 Both BDCA-1+ and BDCA-1- DCs were immunostimulatory in the allo-MLR and 
induced Th1, Th17 and a mixed Th1/Th17 cell type. This lack of difference in their 
function is perhaps surprising, considering there appears to be two discrete populations in 
situ. We interpret these findings as a confirmation of their DC function, and an indication 
that the CD11c+BDCA-1- cells are not monocytes or macrophages. Their ability to 
perform in these assays indicates their antigen-presenting potential, rather than being a 
true characterization of their role in situ during inflammation. There may be several 
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reasons for this lack of difference of function of these two populations, including 
different migration kinetics or ability, or maturation of the BDCA-1- cells during 
migration out of the dermis with concomitant up-regulation of defining DC-functions. 
Thus, although there are several limitations to this system, it is currently the only method 
available to study the potential functions of these cells.  
 
There are several possible mechanisms to explain an increase in inflammatory 
myeloid DCs in psoriasis lesional skin, including arising from in situ DCs in non-lesional 
skin, from circulating DC-precursors or monocytes. These cells may arise from BDCA-1+ 
resident myeloid DCs that down-regulate their BDCA-1 surface expression, or even 
Langerhans cells. This is supported by the xenotransplant psoriasis model, where human 
transplanted non-lesional skin from psoriasis patients is grafted onto immunocompetent 
mice and the grafts become psoriatic without further intervention (Nestle and Nickoloff, 
2005). In this model, resident cells in the non-lesional skin are sufficient and capable of 
inducing the psoriatic phenotype, without any contribution from circulating cells. 
However, the lesional skin may behave differently in this system than in vivo, and other 
cells may take on unconventional roles. 
 
Secondly, these inflammatory myeloid DCs may arise from peripheral blood DC 
precursors, including hematopoietic stem-cell precursors (HSC) multipotent progenitor 
(MPP), common myeloid precursor (CMP), circulating pre-DC (CD11c+ HLA-DRhi, 
CD16+), or monocytes (Massberg et al., 2007; Piccioli et al., 2007; Randolph et al., 
2002; Serbina et al., 2003; Tacke and Randolph, 2006). It is possible that any of these 
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precursor cells are “pre-inflammatory DCs”, migrating into the skin in response to a 
chemokine gradient or other stimulus, supported by our observation of a reduction of all 
circulating DC subsets in psoriasis blood compared to normal. The concept that the 
inflammatory DCs arise from circulating precursors rather than in situ DCs is also 
consistent with other murine models demonstrating that during steady state, Langerhans 
cells and dermal DCs are able to locally proliferate, but during active inflammation there 
is migration of peripheral blood DC precursors into the skin (Bogunovic et al., 2006; 
Ledgerwood et al., 2007; Liu et al., 2007; Massberg et al., 2007).   
 
CD11c+BDCA-1- dermal DCs retain some phenotypic features of their peripheral 
blood precursors, including smaller size, low-level expression of CD14, and CD163, also 
supporting the concept of migration of these cells from the blood. CD163hi cells, 
however, when sorted from psoriasis dermis are not immunostimulatory, thus they can be 
distinguished functionally from the immunostimulatory CD11c+BDCA-1- DC population. 
Other phenotypic markers that have been attributed to both inflammatory DCs and 
inflammatory macrophages include CD68 (Wang et al., 2006), CD32 (Dhodapkar et al., 
2007), and DC-SIGN/CD209 (Granelli-Piperno et al., 2005). The co-localization of some 
of these antigens may also be due to plasticity between these immature DC and 
macrophage populations within the tissue during inflammation. 
 
In addition to characterization of psoriatic myeloid dermal DCs, this paper 
presents evidence for Th17 polarization by psoriatic DCs. Both psoriatic CD11c+BDCA-
1+ resident DCs and CD11c+BDCA-1- DCs had the capacity to polarize Th17 cells, 
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although most polarization was induced by bulk psoriatic dermal cells not damaged by 
sorting.  Moreover, bulk psoriatic émigrés induced Th17 cells producing both IL-17 and 
IFNγ compared to normal skin.  Since psoriasis is now thought of as a mixed Th17/Th1 
disease with strong IL-17 and IFNγ signatures (Blauvelt; Ghoreschi et al., 2007; Lowes et 
al., 2007), it is possible that these IL-17/IFNγ positive T cells induced by psoriatic DCs 
are pathogenic.  
 
In summary, we have demonstrated a marked increase in CD11c+BDCA-1- 
myeloid DCs in psoriasis, and this group of inflammatory DCs contains Tip-DCs. These 
cells are immunostimulatory and capable of Th17 polarization, but their most essential 
contribution may be to secrete inflammatory products such as iNOS, TNF, IL-20, and IL-
23. We hypothesize that the resident BDCA-1+ are likely the myeloid DCs capable of 
classic antigen-presentation to cutaneous T cells, although their dermal location and 
organization into clumps associated with T cells suggests this function may occur within 
the skin environment (“ectopic lymphoid tissue”) rather than in an extracutaneous 
lymphoid organ such as a lymph node (Lew et al., 2004a). In contrast, while BDCA-1- 
DCs are certainly capable of robust antigen presentation in an allo-MLR and have the 
ability to polarize T cells (DC-defining characteristics), their main role may actually be as 
an inflammatory mediator production house, amplifying and maintaining psoriatic 
inflammation. Further studies need to be performed to prove this, dependant on new tools 




positive manner, rather than as a negative population. We need to understand how and 
where these non-resident CD11c+BDCA-1- DCs are generated, in order to be able to 
specifically shut down their production of pro-inflammatory mediators, and bring about 



























Figure 19.  Dendritic cell and macrophage populations in human skin during steady-
state and inflammation.  Non-inflamed skin contains epidermal Langerhans cells, BDCA-
1+ resident dermal DCs, plasmacytoid DCs, and macrophages.  In addition, inflamed skin 
contains a large population of myeloid “inflammatory” DCs. Common markers used to 





CHAPTER 5:  Modulating psoriasis immune pathogenesis with TNF inhibition 
 
 In previous chapters we characterized DC populations in normal and psoriasis 
skin, and showed that the dominant population of inflammatory DCs in psoriatic lesions 
are immunostimulatory.  While these data suggest that DCs play a role in psoriasis 
immunopathogenesis, a DC “knock-out” model is necessary to determine the role of 
these DCs in psoriasis inflammation.  Using the immune modulating drug etanercept, a 
TNF blocking agent, we are able to create an effective knock-out of TNF, a cytokine 
produced by DCs and other cells.  In this chapter we monitored changes in the immune 
milieu of psoriatic plaques during the course of etanercept treatment to further explore 
the role of DCs in psoriasis inflammation.  
Until recently, IFNγ-producing Th1 T cells were implicated as the main 
pathogenic cells (Blauvelt, 2007) as certain T cell-targeted therapies were successful in 
clearing psoriasis (Lowes et al., 2007), and clonal T cells have been found in psoriatic 
skin (Prinz et al., 1994).  However, we are beginning to appreciate that there may be an 
important pathogenic contribution from a recently-recognized subset of T cells – Th17 
cells producing IL-17 and IL-22 (Bettelli et al., 2007; Blauvelt, 2007).  In model systems, 
IL-17 stimulates keratinocyte production of innate inflammatory “danger signals” such as 
defensins and S100 proteins as well as IL-8 neutrophil chemokine (Liang et al., 2006), 
while IL-22 modulates defensins (Wolk et al., 2006) and keratinocyte hyperproliferation 
(Sa et al., 2007; Zheng et al., 2007).  Upstream inducers of Th17 cells are still being 
understood, as most experiments have been performed in murine model systems.  
Mediators may include IL-1, IL-6, and TGFβ, which stimulate differentiation of naïve 
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CD4+ T cells into activated memory Th17 cells (Annunziato et al., 2007; Mangan et al., 
2006; Sutton et al., 2006), and IL-23 which drives Th17 proliferation (Vanden Eijnden et 
al., 2005). 
Th17 T cells producing IL-17 and IL-22 have been implicated as pathogenic in 
murine models of autoimmune diseases, such as experimental autoimmune 
encephalomyelitis (EAE), collagen-induced arthritis (CIA), and inflammatory bowel 
disease (IBD) (Komiyama et al., 2006; Nakae et al., 2002; Nakae et al., 2003; Park et al., 
2005). IL-17 knockout mice are resistant to both EAE and CIA.  Also, mice with EAE 
have increased numbers of Th17 cells, but are resistant to disease if immunized against 
IL-17 (Uyttenhove and Van Snick, 2006).  The dendritic cell (DC) product IL-23, a 
survival factor for Th17 cells, also appears to be necessary for IBD pathogenesis in mice 
(Yen et al., 2006).  Thus a model is emerging of autoimmune inflammation that begins 
with activated antigen presenting cells (APCs) producing IL-23, subsequent Th17 cell 
proliferation and IL-17/IL-22 release, and downstream inflammatory tissue damage.  
Most studies on Th17 cells have been performed in murine models or in vitro. 
However, there is some human data also supporting a similar model of Th17-mediated 
autoimmune inflammation.  Patients with IBD have elevated IL-17 and IL-22 in affected 
colonic tissue and serum, dependent on disease activity and severity (Fujino et al., 2003; 
Nielsen et al., 2003; Te Velde et al., 2006), and patients with rheumatoid arthritis (RA) 
have elevated IL-17 and IL-22 protein in synovial fluid (Ikeuchi et al., 2005; Kotake et 
al., 1999).  In psoriasis patients, IL-17 mRNA has been demonstrated within lesions (Li 
et al., 2004), but protein levels are not increased in the serum (Arican et al., 2005).  IL-22 
protein is increased in psoriatic serum compared to normal, and mRNA is increased in 
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lesional tissue (Wolk et al., 2006).  High levels of IL-23 have also been detected in 
psoriasis lesions (Piskin et al., 2006), and are strongly diminished by effective therapies 
for psoriasis (Lowes et al., 2005b). 
Biological treatments provide researchers with tools to directly target components 
of the immune system, and begin to dissect molecular circuitry and pathogenic pathways.  
Treatment of psoriasis patients with etanercept, a TNFR-Ig fusion protein (etanercept, 
Amgen), presents an opportunity to further understand effects of blocking TNF at a 
molecular and cellular level.  Comparative modulation of Th17 vs. Th1 T cell activation 
in psoriasis within the context of a therapeutic trial has not been previously reported.  We 
found that psoriasis disease improvement correlated with rapid down-modulation of DC 
and Th17 cell products and downstream effector molecules, and final disease resolution 
correlated with late down-modulation of Th1 cells. 
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In vivo anti-inflammatory and immune modulating effects of TNF                 
inhibition at multiple time points during progressively resolving psoriasis             
with drug treatment 
Clinical and histological responses 
In this study, 20 patients were given 50mg of etanercept biweekly for 12 weeks. 
PASI was decreased by a mean of 36% (range 9-67%) after 4 weeks of treatment, and 
69% (range 33-96%) after 12 weeks of treatment (data not shown).  The time course and 
extent of improvement with biweekly etanercept treatment in this trial were similar to 
outcomes seen in larger, double-blind clinical trials (Papp et al., 2005; Tyring et al., 
2006).   
The effects of etanercept on disease histopathology, epidermal thickness, 
expression of K16 (immunohistochemistry and quantitative mRNA measures), and Ki67 
cell counts are illustrated in Figure 20A,B.  After 12 weeks of treatment, epidermal 
thinning and normalization of keratinocyte differentiation occurred in 16 of 20 patients, 
which we considered to be histological responders (Gottlieb et al., 2005).  The data 
presented is from the 16 histological responders in order to study immunologic response 
within the target lesion.   
Average PASI score for histological responders was 7.1 (range 0.6-22, SEM 1.4) 
with an average % clearance of 74.5 (range 38.9-97.5, SEM 4.9) (Figure 20A).  Mean 
epidermal thickness was significantly reduced by week 1 compared to baseline lesional 
skin (p<0.05) .  K16 mRNA levels (a measure of epidermal regenerative activation) and 
Ki67 cell number/mm (a measure of keratinocyte proliferation) were also significantly 
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reduced by week 1 (p<0.001 and p<0.01, respectively) .  Representative haematoxylin 
and eosin (H&E), K16, and Ki67 immunostaining for a responding patient is shown 
(Figure 20B).   Thus, keratinocyte acanthosis, differentiation, and proliferation were all 
rapidly down modulated at week 1 of treatment. 
 
Inflammatory infiltrate in psoriasis skin was reduced with etanercept treatment 
 Non-lesional skin contained relatively low numbers of CD11c+ myeloid DCs, 
CD3+ T cells, and CD163+ macrophages (Figure 20C).  In psoriasis plaques, 
inflammatory cell numbers were increased 2-4 times above normal.  Little or no change 
in inflammatory cell infiltrate was seen by week 1 of etanercept treatment.  By week 2 
cell numbers began to decrease, but did not approximate baseline values until week 12.  
At week 12, CD11c, CD3, and CD163 cell counts were not significantly different from 
non-lesional values.  Representative immunohistochemistry for CD11c, CD3, and CD163 
antigens at each biopsy time point is shown in Figure 20D.   Therefore, decreased dermal 
inflammatory infiltrate with etanercept treatment lagged behind decreased keratinocyte 
acanthosis. 
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Figure 20.  Clinical and histological resolution of psoriasis with etanercept treatment.  
(A) Average PASI scores, epidermal thickness, keratin 16 (K16) mRNA expression, and 
Ki67 cell counts in histological responders (n=16) during treatment with etanercept.  
Clinical response measured at baseline, wks 1, 2, 4 and 12; biopsies evaluated in non-
lesional skin (NL), lesional skin (LS), and in the lesional index plaque at weeks 1, 2, 4, 
and 12.  Baseline lesional values compared with other time points, p<0.05 (*), p<0.01 
(**), and p<0.001 (***).  (B) Histology and immunohistochemistry showing H&E, K16, 
and Ki67 expression during treatment. Size bar = 100µm. (C) CD11c+ myeloid DCs, 
CD3+ T cells, and CD163+ macrophages per mm in non-lesional skin (NL) lesional skin 
(LS), and in the lesional index plaque at weeks 1, 2, 4, and 12.  Baseline lesional values 
compared with other time points, p<0.05 (*), p<0.01 (**), and p<0.001 (***). (D) 
Immunohistochemistry showing CD11c, CD3  and CD163 expression during treatment. 
Size bar = 100µm. 
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Etanercept rapidly down modulated Th17 T cell products and had a delayed effect on 
Th1 and Th2 T cell products 
 IL-17 and IL-22, the hallmark cytokines of Th17 cells, were rapidly down 
modulated in histologic responders by week 1 (p=0.05) and week 2 (p=0.05) of 
etanercept treatment respectively (Figure 21A). Variability in IL-17 expression at weeks 
2 and 4 resulted in p-values that approached significance (p=0.056 and p=0.057, 
respectively).  In contrast, IFNγ, the hallmark cytokine of Th1 response was not down 
modulated until week 12 (p<0.01) (Figure 21B).  LTA-1, another Th1 response cytokine, 
was also down modulated at week 12 (p<0.05) (Figure 21C).   
To assess the biological significance of early Th17 cytokine down modulation and 
late Th1 cytokine down modulation with etanercept treatment, we used multivariate U-
statistics to correlate “Th17 score” (a composite of IL-17 and IL-22 mRNA expression 
values) or “Th1 score” (IFNγ and LTA-1) and correlated them with histological disease 
improvement “response score” (epidermal thickness, K16 expression, and Ki67 counts) 
(Figure 21C).  There was a strong correlation between Th17 cytokines and epidermal 
response score (R=0.89, p=3.7 X 10-6) and less so between Th1 cytokines and epidermal 
response score (R=0.49, p=0.055).  We further confirmed biological significance of early 
Th17 down modulation by measuring genes regulated by IL-17, CCL20 and DEFB4 
(Figure 21D).  CCL20 and DEFB4 were both down modulated by week 1 of etanercept 
treatment (p=0.01, p=0.05) and were consistently suppressed at all weeks of treatment.  
In contrast, an IFNγ regulated gene, MX-1, was not significantly reduced until week 4 
(p=0.05) and even more strongly suppressed by week 12 (p<0.001) (Figure 21E).  Also of 
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interest was IL-4, the defining cytokine of the Th2 T cell, was up regulated at week 12 
(p=0.09) (Figure 21F).  
Other inflammatory cytokines rapidly down modulated with etanercept were IL-
1β (week 1, p<0.01), IL-6 (week 2, p<0.05), and IL-8 (week 1, p<0.01), findings 
previously reported by our group at 1 month, the earliest time point of that study 
(Gottlieb et al., 2005).  In contrast, TGFβ was not significantly altered with treatment 
(Figure 22).  In summary, while Th17 T cell products and downstream effector molecules 
regulating keratinocyte hyperplasia are modulated rapidly during the course of etanercept 
treatment, Th1 and Th2 products are modulated late, months after disease has 
significantly improved.
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Figure 21. Th17 cell products and downstream mediators are rapidly down modulated 
with etanercept treatment compared to Th1 and Th2 cell products. mRNA expression 
normalized to HARP for (A) Th17 cell products IL-17 and IL-22 and (B) Th1 cell 
products IFNγ and LTA-1.  (C) Multivariate U-statistics correlating the change in Th17 
or Th1 cell products with histological response (epidermal thickness, K16, Ki67) over 
time.  (D) Downstream effectors of Th17 cells, CCL20 and DEFB4 (b-defensin) (E) 
Downstream effector of Th1 cells MX-1. (F) Th2 cell product IL-4.  All mRNA 
evaluated in non-lesional skin (NL), lesional skin (LS), and in the lesional index plaque at 
weeks 1, 2, 4, and 12.  Baseline lesional values compared with other time points, p<0.05 
(*), p<0.01 (**), and p<0.001 (***). 
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Figure 22.  IL-1β, IL-6, and IL-8 are rapidly down modulated with etanercept treatment. 
mRNA expression normalized to HARP for IL-1β, IL-6, IL-8, and TGFβ in non lesional 
skin (NL) lesional skin (LS), weeks 1, 2, 4 and12. Baseline lesional values compared 
with other time points, p<0.05 (*), p<0.01 (**), and p<0.001 (***).  
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Products of TipDCs were rapidly down modulated with etanercept treatment 
We have previously described the TNF and inducible nitric oxide synthase 
(iNOS) producing DC (Tip-DC) as a major pathogenic cell in psoriasis (Lowes et al., 
2005a).  Using RT-PCR and double-label immunofluorescence we show that Tip-DC 
products were rapidly down modulated with etanercept treatment (Figure 23A).  iNOS 
mRNA was significantly decreased by week 2 (p<0.05), IL-20 mRNA decreased by week 
1 (p<0.05), and both IL-23 subunits (p19 and p40) were reduced by weeks 1 and 2 
(p=0.06, p<0.05 respectively).  In contrast, transcription of the IL-12 p35 subunit was not 
modulated by etanercept. 
We confirmed that IL-20 was primarily a product of CD11c+ myeloid DCs in 
untreated psoriasis using double-label immunofluorescence showing >90% co-
localization (yellow color) of IL-20 antigen with CD11c antigen in baseline lesional 
sections (Figure 23B).  IL-20+CD11c+ cells were clustered in elongated dermal papillae 
where there is an extensive vascular supply, and a few cells invaded the epidermis.  At 
week 2 of etanercept treatment <10% of CD11c+ cells produced IL-20, and by week 12 
no visible overlap was apparent. Similarly, IL23p40 subunit was produced by 100% of 
CD11c+ cells in psoriasis lesional skin, but was not detected at weeks 2 and 12 of 
etanercept treatment (Figure 23C).  
TNF was produced in >95% of CD11c+ DCs within untreated psoriasis plaques as 
indicated by the yellow cells clustering near the dermal-epidermal junction and 




visible overlap was apparent.  iNOS protein in CD11c+ DCs is also down modulated by 
etanercept treatment, as previously published by our group (Gottlieb et al., 2005).  Hence, 
iNOS, TNF, IL-20, and IL-23 are Tip-DC products down modulated within the first 2 
weeks of etanercept treatment.
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Figure 23.  Inflammatory DC cell products are rapidly down modulated with etanercept 
treatment. (A) mRNA expression normalized to HARP for inflammatory DC cell 
products iNOS, IL-20, IL-23 p19, IL-23/IL-12 p40, and IL-12 p35 in non-lesional skin 
(NL) lesional skin (LS), weeks 1, 2, 4 and 12. Baseline lesional values compared with 
other time points, p<0.05 (*), p<0.01 (**), and p<0.001 (***). (B-D) Double-label 
immunofluorescence of myeloid DCs (CD11c) and various mediators (IL-20, IL-12/23 
p40, and TNF) demonstrating co-expression (yellow color) in baseline lesional skin, 
compared to weeks 2 and 12, showing a reduction in myeloid DCs and their products 
with etanercept treatment. (B) CD11c (green) and IL-20 (red); (C) CD11c (green) and IL-
23/IL-12 p40 (red); (D) CD11c (red) and TNF (green). The white line identifies the 




Myeloid DCs in the skin down regulated maturation markers by week 2 of etanercept 
treatment 
 Single antigens specific for mature DC identification include CD83 and/or DC-
LAMP.  In responding patients, CD83+ DCs were scattered throughout psoriatic 
epidermis and upper-dermis, while DC-LAMP+ DCs aggregated together in clusters in 
the upper reticular dermis (Figure 24A).  CD83 and DC-LAMP were significantly 
decreased by weeks 1 and 2 of etanercept treatment (p<0.01 and p<0.05, respectively) 
(Figure 24B).  The larger average number of CD11c+ myeloid cells in lesional skin (247 
cells/mm, standard error of the mean (SEM) = 31.9, Figure 20C) compared to CD83+ (9 
cells/mm, SEM=3.0, Figure 24B) and DC-LAMP+ DCs (49 cells/mm, SEM=6.8, Figure 
24B) suggests that mature DCs were a subset of lesional DC infiltrate. 
 Maturation of migrant dermal DCs as measured by levels of surface co-
stimulatory molecules, was also decreased by week 2 of etanercept treatment (Figure 
24C).  Using FACS analysis, we gated on cells that met the classic definition of DCs 
(Lin-CD11c+HLA-DR+) and determined the expression levels of CD86, HLA-DR, CD40, 
and CD11c on cells emigrating from the dermis at baseline and week 2 (n=5 patients).  At 
baseline (week 0) there was a subset of CD86hiHLA-DRhi cells that was not present after 
2 weeks of etanercept treatment.  Mean fluorescence intensity (MFI) of DC activation 
markers CD86, HLA-DR, and CD40 decreased in all week 2 samples (representative 




samples and increased in 2 samples.  Cell size (FSC-H) and cell complexity (SSC-A) 
decreased in all samples (data not shown). Thus, myeloid dermal DC activation (CD86, 
HLA-DR, CD40) and cell size/complexity are reduced by week 2 of etanercept treatment 
compared to baseline.
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Figure 24.  DCs down regulate maturation and co-stimulatory molecules with etanercept 
treatment.  (A)  Immunohistochemistry for mature DC markers CD83 and DC-LAMP in 
non-lesional skin (NL), lesional skin (LS), and in the lesional index plaque at weeks 1, 2, 
4, and 12. Size bar = 100µm. (B) Quantification of CD83+ and DC-LAMP+ cells per mm 
(n=16) during etanercept treatment. Baseline lesional values compared with other time 
points, p<0.05 (*), p<0.01 (**), and p<0.001 (***). (C) FACS analysis at baseline (week 
0) and matched week 2 etanercept-treated lesional dermal single cell suspensions. 
Acquired cells gated on myeloid DCs (Lin- HLA-DR+ CD11c+).  MFI is indicated in 
upper right corner of each histogram, isotypes shown in light grey. 
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Etanercept blocked in vitro derived DC maturation and  IL-23 production, 
immunostimulatory capacity, and shifted differentiation towards a macrophage-like 
phenotype 
 Monocyte derived DCs cultured with etanercept decreased CD86 expression 3-
fold and HLA-DR expression 5-fold (Figure 25A).  CD11c expression decreased slightly, 
as did cell granularity (SSC-A).   RT-PCR on three paired biological replicates showed a 
significant decrease in IL-23 subunits p19 and p40 (p=0.02 and p=0.05, respectively) but 
there was no significant decrease in IL-12 subunit p35 (p=0.25) (Figure 26).  Likewise, 
IL-6 was down regulated (p=0.04) while TGFβ1 was up regulated (p=0.05).  MoDCs 
cultured with etanercept were also an average of 2-3 fold less stimulatory than control 
DCs in a mixed leukocyte reaction (MLR) (n=2).  Etanercept did not affect stimulation of 
T cells alone or T cells stimulated with CD3/CD28 beads (Figure 25B). 
Gene array on control monocyte-derived DCs compared to those cultured with 
etanercept revealed that CD163, a macrophage scavenger receptor, was strongly up 
regulated (6.5-fold increase, p<0.05) (Figure 25C).  We confirmed these results using 
FACS analysis, and identified upregulation of CD163 protein on CD11c+ cells matured 
with etanercept compared with control DCs (Figure 25D).  Etanercept had no significant 
effect on expression of Th1 (IFN-γ) or Th17 (IL-17 and IL-22) cytokine mRNAs in 
activated T cells with or without etanercept (n=3) (data not shown). 
The small number of non-responders in this trial (n=4) limits statistical 




non-responders in Figure 27.  Of note, IL-17 response genes CCL20 and DEFB4 are not 
downmodulated as rapidly or consistently in non-responders (Figure 27C) as they are in 
responders (Figure 21D).  Reactive epidermal hyperplasia is also not suppressed to the 
same extent as in responders.
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Figure 25.  In vitro monocyte derived DCs generated in the presence of etanercept are 
less mature, less immunostimulatory, and express macrophage antigen CD163.  (A) 
FACS analysis of monocyte derived DCs generated without or with etanercept. Acquired 
cells gated on myeloid DCs (Lin- HLA-DR+ CD11c+).  MFI is indicated in upper right 
corner of each histogram. Isotypes shown in light grey.  (B) Mixed leukocyte reaction 
comparing monocyte derived DCs matured with and without etanercept (T cells + iDC). 
“T cells alone” and “T cells +CD3/28” serve as negative and positive controls 
respectively.  Percent proliferation is indicated in lower left corner of each FACS plot.  
(C) Comparison of CD163 mRNA expression (gene array) in monocyte derived DCs 
generated without (blue) or with (red) etanercept, p<0.05 (*). (D) Increased surface 
expression of CD163 on monocyte derived DCs generated with etanercept confirmed by 
flow cytometry.  
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Figure 26.  In vitro derived DCs matured with etanercept produce less IL-23 and are less 
immunostimulatory than control DCs. mRNA expression normalized to HARP for p19, 
p40, p35, IL-6, and TGFβ in vitro derived DCs matured without (control) and with 
etanercept (+ etanercept). 
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Figure 27.  Non-responder data.  (A) Average PASI scores, epidermal thickness, keratin 
16 (K16) mRNA expression, and Ki67 cell counts in non-responders (n=4) during 
treatment with etanercept.  Clinical response measured at baseline, wks 1, 2, 4 and 12; 
biopsies evaluated in non-lesional skin (NL), lesional skin (LS), and in the lesional index 
plaque at weeks 1, 2, 4, and 12.  Baseline lesional values compared with other time 
points, p<0.05 (*), p<0.01 (**), and p<0.001 (***).  (B) Histology and 
immunohistochemistry showing H&E, K16, and Ki67 expression during treatment. Size 
bar = 100µm.  (C) mRNA expression normalized to HARP for Th17 cell products IL-17 
and IL-22, Th1 cell products IFNγ and LTA-1, downstream effectors of Th17 cells, 
CCL20 and DEFB4 (b-defensin), downstream effector of Th1 cells MX-1, and Th2 cell 
product IL-4.  All mRNA evaluated in non-lesional skin (NL), lesional skin (LS), and in 
the lesional index plaque at weeks 1, 2, 4, and 12.  Baseline lesional values compared 
with other time points, p<0.05 (*), p<0.01 (**), and p<0.001 (***). (D)  
Immunohistochemistry for mature DC markers CD83 and DC-LAMP in non-lesional 
skin (NL), lesional skin (LS), and in the lesional index plaque at weeks 1, 2, 4, and 12. 






This study contains new information that informs on two separate but related 
topics:  therapeutic mechanisms of the TNF inhibitor etanercept, and the network of 
inflammatory cytokines and leukocytes that drive psoriasis pathogenesis.  Presently, there 
are three TNF inhibitors in widespread use for treatment of psoriasis, psoriatic arthritis, 
rheumatoid arthritis, inflammatory bowel disease and ankylosing spondylitis – Infliximab 
and adalimumab are monoclonal TNF antibodies, and etanercept is a dimeric TNFRII Fc 
fusion protein (Atzeni et al., 2005; Scott and Kingsley, 2006).  While often considered as 
a therapeutic class, these agents are structurally different, have different affinities for 
TNF, and are not uniformly effective for all inflammatory diseases (Furst et al., 2006).  
Although over one million patients have been treated with these drugs, there is 
surprisingly little data on therapeutic mechanisms in human inflammatory diseases.  In 
this paper, we show that psoriasis disease improvement correlated with early reduction in 
DC and Th17 cell products and downstream effector molecules, and final disease 
resolution correlated with late down modulation of Th1 cells. 
  
When considering previous research on TNF inhibitor mechanism, it is useful to 
divide response into early (hours to days) versus late (weeks to months) effects.  In the 
case of infliximab and adalimumab, there are reports suggesting that broad apoptosis of 
inflammatory leukocytes is induced within hours of drug delivery (Lugering et al., 2001; 
Shen et al., 2005).  With these agents, reduction of cytokine-driven inflammation is likely 
a combination of inhibition of TNF-dependent cytokine production, as well as reducing 
cytokine-producing cells via apoptosis.  Early apoptosis, however, is not a feature of 
 114 
etanercept treatment.  Studies on psoriasis lesions show some leukocyte apoptosis after 1 
month of treatment (Malaviya et al., 2006), suggesting that apoptosis is a secondary 
mechanism following growth factor/TNF withdrawal.   
 
In this paper we propose that an early mechanism of etanercept is to inhibit 
inflammatory DC cytokine production and maturation, leading to reduction in activity of 
Th17 T cells. Recently, a new type of inflammatory myeloid CD11c+ DC was described 
in psoriasis, the Tip-DC (Lowes et al., 2005a). This cell type was first identified in a 
murine model of innate immune response to listeria infection (Serbina et al., 2003).  In a 
previous clinical trial using etanercept, iNOS mRNA and protein, along with various 
other DC and T cell inflammatory cytokines and chemokines, were decreased by 1 month 
treatment (the earliest time point in that study) (Gottlieb et al., 2005).  Our current study 
uses even earlier time points to recreate the hierarchy of TNF dependent mediators, and 
separate primary (early) versus secondary (late) response.  We now show that multiple 
inflammatory products of TipDCs, including iNOS, TNF, IL-20, and IL23 p40 subunit, 
are reduced within 1-2 weeks after beginning etanercept, while the number of CD11c+ 
DCs in the tissue is minimally affected during this time, suggesting initial blockade of 
cytokine production by these cells rather than cell reduction.  This suggests that TNF is 
an autocrine or paracrine inducer of TipDC inflammatory products, which is blocked by 
etanercept.  This direct effect on DCs is supported by our in vitro studies with monocyte-
derived DCs showing that etanercept blocked up regulation of co-stimulatory and MHC-
II molecules, IL-23 production, and immunostimulatory capacity. 
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The early modulation of Tip-DCs by etanercept may rapidly impact Th17 cells, 
beginning the process of molecular resolution before reduction in cellular infiltrates and 
long before clinical resolution. Our proposed psoriatic inflammatory pathway involves 
the production of IL-23 from these inflammatory Tip-DCs causing proliferation of Th17 
cells, with subsequent induction of IL-17, IL-22, and other products (Figure 36). IL-17 
appears to serve as an inducer of keratinocytes to produce antimicrobial peptides like β-
defensin 4, S100 acute phase proteins, and chemokines such as IL-8 (Kao et al., 2004).  
Models of psoriasis suggest that IL-22 strongly induces keratinocyte hyperplasia, and 
mediates IL-23 induced dermal inflammation and acanthosis (Zheng et al., 2007).  All of 
these products were down modulated within 1-2 weeks of etanercept treatment. The 
involvement of Th17 cells in psoriasis may now help explain the following: hyperplasia 
of psoriatic keratinocytes (IL-22); why psoriatics are relatively protected from bacterial 
infection (defensins); and why neutrophils that are normally reserved for acute 
inflammatory processes appear in a chronic inflammatory disease (IL-8).  Moreover, 
histological resolution of the disease, as defined by decreased epidermal thickness and 
normalization of keratinocyte proliferation (Ki67) and differentiation (K16), correlates 
with rapidly decreased Tip-DC and Th17 products.  Thus, these results suggest that Th17 
cells are important for disease pathogenesis, and may be modified by etanercept at an 
early time point. 
 
Finally, while there is an emerging role for Th17 driving inflammation in 
psoriasis, Th1 cells may still be important for final disease resolution. While Tip-DC and 
Th17 products are down modulated within 2 weeks of etanercept treatment, IFNγ is not 
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decreased until week 12, and STAT-1 (an IFNγ-dependent transcription factor) is not 
significantly decreased until several months of treatment (Gottlieb et al., 2005).  So 
although histological disease resolution begins within weeks, complete remission does 
not occur until several months of treatment when both Th17 and Th1 products have been 
down modulated.  IFNγ is a major inducer of MHC-II, and acts synergistically with IL-17 
to upregulate keratinocyte ICAM-1 adhesion molecules and IL-8 production (Teunissen 
et al., 1998), suggesting that Th1 cells may be important for leukocyte activation.  
Activated T cells are required in the epidermis for psoriasis to develop (Conrad et al., 
2007; Conrad et al., 2005), and most epidermal T cells are Type 1 CD8+ cells 
(Gudjonsson et al., 2004); it follows that they must be ablated for disease resolution. 
Thus, while Th17 cells may be the major drivers of keratinocyte hyperplasia and 
inflammatory cytokine production, Th1 cells may be important for leukocyte activation 
and for sustaining a network of over 100 genes linked to IFNγ signaling (Lew et al., 
2004b). In addition, there may be important functional interactions between Th17 and 
Th1 T cells, as cross-regulation has been recently demonstrated in model systems (Nakae 
et al., 2007; Park et al., 2005).  More work needs to be done to delineate the specific 









CHAPTER 6:  Global characterization of genes modulated by etanercept 
 
 In the previous chapter we used RT-PCR as a genomic tool for probing specific 
gene products we hypothesized were modulated by etanercept.  In this chapter we use 
gene array as a tool for probing the genomic profile of etanercept modulated genes in an 
unbiased way.  Using gene array we confirm our initial hypothesis that IL-17 and TNF 
pathways are rapidly downregulated with etanercept treatment and IFNγ is 
downregulated later during final disease resolution.  We also show that myeloid genes are 
the first genes modulated by blocking TNF, and that T cell genes are affected 
secondarily.  We propose that the close association of downregulated TNF and IL-17 
pathways is through inhibition of DC-dependent IL-23 production. 
 
Gene array analysis on skin samples from the etanercept clinical trial 
Comparison of “psoriasis genes” identified using the newer Affymetrix U133A2.0 
platform with previously published gene lists using the Affymetrix U95 platform 
 Previous work that used gene array technology to identify transcripts that were 
differentially expressed among psoriasis lesional and non-lesional paired samples was 
done on the 63,100-element Affymetrix U95A, B, C, D and E platform (Zhou et al., 
2003).  The samples in this trial were interrogated using the 22,215-element Affymetrix 
U133A2.0 platform.  On the newer U133A2.0 platform, we found that 599 genes (728 
probesets) were upregulated 2-fold or more in lesional skin compared to non-lesional 
skin, and 732 genes (890 probesets) were downregulated to this extent.  Overall, the 
U133A2.0 platform detected more genes differentially expressed than the previous 
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studies using U95 array sets, despite our using stricter statistical criteria to detect 
differences. 
 
Cluster analysis on genes modulated by etanercept 
We first identified genes that were significantly different from lesional baseline at 
any time during etanercept treatment (FDR<0.05 and 2-fold change), and found that 
etanercept downregulated 978 probesets and upregulated 999 probesets. 
 For cluster analysis on genes modulated by etanercept, we clustered time profiles 
for responders using Consensus Clustering method to determine the optimal number of 
clusters in the hierarchical clustering algorithm. Consensus Clustering produces the 
Consensus Matrix and the delta area curve for each scenario of user defined number of 
clusters (k) in each gene set (Swift et al., 2004).  
In the case of genes downmodulated by etanercept, Consensus Clustering 
identified a scenario with a high delta area for either 3 or 4 clusters (k=3 or k=4) (Figure 
28A). Visualization of the Consensus Matrix showed more defined clustering for k=4 
(Figure 28B).  The average gene expression profile in each cluster at each time point is 
visualized in Figure 28C (left) with corresponding heatmap (right). Cluster #1 containing 
31 probesets was defined as “down early,” Cluster #2 with 168 probesets was “down 
mid,” Cluster #3 with 616 probesets was “down late,” and cluster #4 with 163 probesets 
was “down latest”. The relative velocity of gene downmodulation is visualized in each 
cluster graph by the dotted red line, marking the time taken to achieve 1/2 maximal gene 
expression (t1/2). “Down early” genes achieved t1/2 between weeks 0 and 1 of etanercept 
treatment, “down mid” t1/2  fell between weeks 1 and 2, “down late” was between weeks 2 
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and 4, and “down latest” was between weeks 4 and 12. Downregulated genes from 
clusters 2-4 are listed in Supplementary Table 2, and “down early” cluster #1 genes with 
corresponding heatmap is shown in Figure 2a. 
 Etanercept upregulated genes clustered into three groups (Figure 29A, B).  Cluster 
#1 genes (23 probesets) were upregulated “early”, cluster #2 genes (43 probesets) were 
























Figure 28. Gene array analysis groups genes down-modulated by etanercept into 4 
clusters: down early, down mid, down late, and down latest. Consensus Clustering on 
genes downmodulated with etanercept produced a delta curve (A) and Consensus Matrix 
(B) that identify 4 clusters (C).  Red dashed line denotes time taken to achieve 1/2 
maximal gene expression.  Corresponding heat map for each cluster is to the right. 
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Figure 29. Gene array analysis groups genes upregulated by etanercept into three 
clusters:  up early, up mid, and up late.  Consensus Clustering on genes upregulated with 
etanercept produced a delta curve (A) and Consensus Matrix (B) that identify 3 clusters 
(k=3) as the best clustering model (C).  Red dashed line denotes time taken to achieve 1/2 
maximal gene expression.  Corresponding heat map for all upregulated genes (D). 
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Genes rapidly downmodulated during etanercept treatment 
To identify which cell types are rapidly modulated by TNF inhibition, we grouped 
“down early” cluster #1 (Figure 30A) genes according to the cell lineage(s) in which the 
genes are expressed (Figure 30B).  These “down early” genes were mostly products of 
activated myeloid cells (monocytes, DCs, macrophages, or osteoclasts), but were also 
expressed by T cells, endothelium, keratinocytes, or were ubiquitously expressed.  As 
previously reported, cutaneous CD11c+ cell counts remain constant during the first week 
of etanercept treatment (Zaba et al., 2007a), suggesting that rapidly decreased myeloid 
gene expression was secondary to cell inhibition, not decreased cell number.  In 
summary, these data suggest that myeloid cell inhibition is the earliest target for TNF 
inhibitors. 
Mechanisms of TNF inhibition were further elucidated by classifying “down 
early” genes according to gene function (Figure 30C).  Genes regulating cell 
proliferation/ mitosis rapidly downmodulated with etanercept were CDC6, CHEK1, 
AURKA, DUSP3, and SPC25.  Keratinocyte differentiation genes were DSC2 and 
SPRR3;  Leukocyte chemotaxis genes were IL8, CCL4, CCL3, FPR1, PLAUR, and 
LIPG;  Lipid metabolism genes were LIPG, LRP8, and LDLR;  Reactive oxygen species 
modulating genes were LIPG, CCL3, LRP8, IL-19, and FPR1 and SLC23A2; Pro and 
anti-apoptotic genes were IL-19 and BCL2A1 respectively; Anti-microbial / anti-viral 
genes were HBEGF and APOBEC3A; and osteoclastogenesis promoting genes were 





1b, FPR1, TNIP3, LIPG, SPRR3, and HBEGF, although it can be argued that all genes 
rapidly downmodulated by TNF inhibition are likely downstream of NFκB.  Implications 
of these rapidly downmodulated genes for psoriasis disease pathogenesis are further 
elucidated in the discussion of this thesis. 
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Figure 30. Genes downmodulated rapidly by etanercept. 27 genes (31 probesets) were 
rapidly downmodulated with etanercept treatment (A).  Most of these genes were 
produced by myeloid lineage cells (B).  Primary function of rapidly downmodulated 
genes are listed (C). 
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Gene set enrichment analysis on genes downmodulated by etanercept  
 After establishing myeloid cell inactivation as a likely primary target of TNF 
inhibition, we used Gene Set Enrichment Analysis (GSEA) to identify secondary and 
tertiary effects of etanercept (Table 3).  GSEA confirmed that  “down early” cluster #1 
was enriched with TLR/ NFκB signaling pathway activation genes and cytokine-cytokine 
receptor interactions. Clusters #2 and #3 were enriched with cell cycle genes, p53 
signaling pathway genes, pyrimidine metabolism, folate biosythesis, amino acid 
metabolism, epithelial cell signaling, and starch/sucrose metabolism genes – all indicators 
of decreased rate of keratinocyte proliferation. “Down latest” cluster #4 was again 
enriched with TLR/ NFκB signaling pathway genes during final disease resolution.  
Therefore, etanercept directly decreased TNF-dependent myeloid cytokine/chemokine 
production, secondarily decreased keratinocyte proliferation/differentiation, and lastly 
decreased leukocyte activation even more extensively during final disease resolution. 
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Table 3.  Gene set enrichment analysis on genes downmodulated by etanercept.  Gene Set 
Enrichment Analysis on downregulated genes to reveal over-represented pathways within 
each cluster. 
 
KEGGID Pathway p-value odds 
ratio 
cluster 
4620 TLR signaling pathway 6X10-4 13.2 1 
4060 Cytokine-cytokine receptor 
interaction 
2X10-3 7.2 1 
4110 Cell cycle 6X10-6 7.3 2 
4115 p53 signaling pathway 5X10-4 6.8 2 
240 Pyrimidine metabolism 6X10-3 4.8 2 
860 Porphyrin and chlorophyll 
metabolism 
2X10-3 5.1 3 
790 Folate biosynthesis 6X10-3 4.1 3 
220 
 
Urea cycle and 
metabolism of amino 
groups 
7X10-3 4.8 3 
5120 
 
Epithelial cell signaling in 
Helicobacter pylori 
infection 
8X10-3 3.1 3 
500 Starch and sucrose 
metabolism 
0.01 2.9 3 
4620 TLR signaling pathway 0.01 4.1 4 
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Confirmation of gene array results with  RT-PCR and immunofluorescence 
 Rapidly downmodulated genes were confirmed using RT-PCR and 
immunofluorescence (Figure 31).  “Down early” cluster #1 chemokines IL-19, CCL3 
(MIP1α), and CCL4 (MIP1β) expression was decreased by 62%, 54%, and 50% (p<0.05, 
p<0.05, p=0.055, respectively) after 1 week of etanercept treatment (Figure 31A).   
Another “down early” cluster #1 gene, heparin-binding epidermal growth factor-
like protein (HBEGF), was a rapidly downmodulated myeloid cell product (Figure 31B). 
Using image-J we measured red (HBEGF), green (CD11c), and red+green (yellow) pixel 
area normalized to dermal area in non-lesional, lesional, week 2, and week 12 double-
labeled immunofluorescence images.  Using this digital analysis technique we compared 
relative HBEGF and CD11c expression as well as overlap (CD11c+ cells expressing 
HBEGF).  After 2 weeks of etanercept treatment, there is a 70.0% reduction in CD11c+ 
cells that express HBEGF and a 58.3% reduction in total HBEGF production compared to 
lesional baseline. HBEGF is implicated in promotion of antimicrobial expression in 
keratinocytes by binding to the EGF receptor, upregulating defensin β-103A (formerly 
DEFB3) and lipocalin.  Thus, both RT-PCR and immunofluorescence confirmed rapid 
downregulation of gene array-defined cluster #1 genes. 
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Figure 31.  Confirmation of gene array results with RT-PCR and immunofluorescence.  
RT-PCR on IL-19, CCL3, and CCL4 cytokines show downregulation by week 1 of 
etanercept treatment (A) (* p<0.05, **p<0.01, ***p<0.001).  (p-value of CCL4 at week 1 
= 0.055).  Double label immunofluorescence shows rapid downregulation of HBEGF 
(red) and CD11c (green) after 2 weeks etanercept treatment (B).  Size bar = 100µm 
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Comparison of early and late response genes with clinical markers of disease resolution 
Cluster #1 etanercept early response cytokines confirmed by RT-PCR include IL-
19, CCL3, and CCL4 (Figure 31A) as well as IL-8 and IL-1β which were also rapidly 
downregulated by week 1 as previously reported (p<0.01 and p<0.05, respectively)  
(Zaba et al., 2007a).   To understand how early response gene downregulation may 
impact clinical phenotype and histological disease resolution, we graphed early response 
genes (Figure 32, dashed lines) and clinical disease markers (Figure 32, solid lines) by 
percent remission.  As a point of comparison, we included RT-PCR data from known 
etanercept late response gene IFNγ (Figure 32, dotted red line).  The four 
clinical/histological disease markers we examined were PASI, epidermal thickness, Ki67 
cell counts, and K16 gene expression:  PASI is a global measurement of % body mass 
covered with psoriasis plaque, epidermal thickness is a linear measurement (in mm) on 
H&E sections, Ki67 is a marker of  cell proliferation, and K16 gene expression indicates 
aberrant keratinocyte maturation.  K16 expression was rapidly downregulated along with 
etanercept early response genes, suggesting that aberrant epidermal differentiation was 
caused by TNF directly or by TNF dependent early response genes.  In contrast, both 
markers of keratinocyte proliferation (Ki67 and epidermal thickness) were downregulated 
later, a result that was supported by Gene Set Enrichment Analysis (Table 3) in which 
keratinocyte proliferation genes were enriched in clusters 2 and 3.  PASI was located in 
between keratinocyte proliferation markers and IFNγ etanercept late response gene, 
suggesting that global disease resolution depended on both early and late TNF response 
gene downregulation. 
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Figure 32. Comparison of early and late response genes with clinical markers of disease 
resolution.  % remission is calculated as log2(t / NL) where t = 0, 1, 2, 4, or 12.  Data for 
IFNγ, K16, IL-19, CCL4, IL-8, CCL3, and IL-1β was obtained using RT-PCR.  PASI is a 
clinical score of psoriasis disease severity, thickness is a measure (in mm) of histologic 
epidermal thickness, and Ki67 cell count/ mm2 was obtained from immunohistochemistry 




IL-17 and TNF response genes are downregulated more rapidly than IFNγ response 
genes during etanercept treatment 
 To assess the relative contribution of IL-17, TNF, and IFNγ response genes to 
etanercept-mediated disease resolution, we first defined a set of keratinocyte genes 
induced when cultured with each cytokine for 24 hours (n=3 for each condition) 
(Nograles et. al., submitted).  IL-17 modulated 41 keratinocyte genes, TNF modulated 
121 genes, and IFNγ modulated 607 genes. Each cytokine pathway gene set was then 
culled from the etanercept trial data set and normalized to baseline non-lesional 
expression over time (Figure 33A).  IL-17 pathway genes were overexpressed in lesional 
biopsies and decreased rapidly with etanercept treatment. TNF pathway genes were not 
as highly expressed as IL-17 genes, but also decreased rapidly with etanercept treatment.  
In contrast, IFNγ modulated gene expression increased during the first of etanercept 
treatment, and was not significantly downmodulated until week 12.  Downregulation of 
IL-17 pathway genes correlated significantly with decreased epidermal thickness, a 
histologic indicator of disease resolution (r=0.85, p<0.05) (Figure 33B).  Neither TNF 
pathway nor IFNγ pathway gene modulation correlated significantly with decreased 
epidermal thickness (r=0.62 and r=0.35, respectively).   
 Intersection of IL-17 and TNF pathway gene lists revealed 19 commonly 
modulated genes, 22 unique “IL-17 only” genes, and 102 unique “TNF only” genes 
(Figure 33C).  IL-17 and TNF common pathway genes were highly expressed in baseline 
lesional skin, more so than unique IL-17 or unique TNF genes (Figure 33C) suggesting 
cooperativity between IL-17 and TNF pathways.  Correlation of each gene set with 
epidermal thickness (Figure 33D) showed significant correlation for cooperatively 
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regulated IL-17/TNF genes (r=0.71, p<0.05) and for uniquely IL-17 regulated genes 
(r=0.73, p<0.05), but not for uniquely TNF regulated genes (r=0.61, p<0.05).   
All six pathway mean expression values are plotted in Figure 33E, demonstrating 
the relatively large downregulation of cooperative IL-17/TNF and IL-17 genes during 
etanercept treatment compared to genes in other pathways.  To visualize relative velocity 
of pathway recovery to non-lesional expression levels, we plotted mean gene expression 
% remission over time (Figure 33F).  As suggested by the mean expression curves in 
Figure 32, we found that all pathways had a similar velocity of recovery except for the 
IFNγ pathway, which was downregulated later.  These results solidify the importance of 
IL-17 pathway downmodulation for etanercept-mediated psoriatic phenotype resolution.   
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Figure 33. IL-17 and TNF response genes are downregulated more rapidly than IFNγ 
response genes during etanercept treatment.  Mean expression of IL-17, TNF, IFNγ, IL-
17 and TNF, IL-17 only, and TNF only pathway genes in patients treated with etanercept 
over time (A,C,E).  U-score correlation of pathway data and epidermal thickness (a proxy 






Functional link between TNF inhibition and Th17 downmodulation 
 Previous work established that p40 IL-23/IL-12 subunit, but not p35 IL-12 
subunit, is a TNF early response gene produced by activated dendritic cells (Zaba et al., 
2007a).  As IL-23 supports the differentiation and survival of IL-17 producing Th17 
cells, it is likely that TNF modulates Th17 cells indirectly through p40 expression – a 
hypothesis supported by rapid downmodulation of IL-17 pathway genes with TNF 
inhibition (Figure 33A). To further explore the link between TNF inhibition and rapid 
downmodulation of Th17 pathway genes, we performed an allo-MLR mixing psoriatic 
dermal émigrés (n=3) with donor T cells ± p40 neutralizing antibody (Figure 34).  p40 
neutralization significantly decreased CD4+ T cell IFNγ production by 46% (p<0.05), and 
IL-17 production by 66% (p<0.05), with a reciprocal 44% upregulation of Th2 cytokine 
IL-4 (p<0.05) (Figure 34A).  A representative patient’s FACS plots are shown in Figure 
34B.  Neutralization of p40 did not; however, inhibit T cell proliferation (Figure 34C), 
confirming that downregulation of cytokine production was not due to decreased cell 
viability.  These results provide functional validation for the link between TNF inhibition 
and rapid downregulation of Th17 adaptive immunity. 
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Figure 34. Functional link between TNF inhibition and Th17 downmodulation.  MLR 
using psoriatic dermal émigrés and donor T cells with or without p40 neutralizing 
antibody.  Intracellular cytokine staining determines effects of p40 blockade on CD4+ T 
cell IFNγ, IL-17, and IL-4 production (A,B).  CFDA labeling measures T cell 
proliferation with and without p40 neutralization (C). 
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Differences between patients who responded to etanercept treatment and those who did 
not 
 Applying consensus clustering to non-responder vs. responder data normalized to 
baseline, the delta area statistics suggested there were either 6 or 7 gene clusters (Figure 
35A). By inspection of the consensus matrix, a 7 cluster structure clearly emerged 
(Figure 35B). Gene expression values for genes within the four largest clusters are 
presented in Figure 35C. Cluster #2 is likely the most biologically meaningful to explain 
differential response, as non-responders had elevated expression of these genes 
throughout treatment, while responder gene expression steadily declined. Cluster #2 
genes and the corresponding heatmaps for non-responders and responders are shown in 
Figure 35D.  
In contrast to leukocyte-dominated genes downregulated rapidly in patients who 
responded to etanercept treatment (Figure 30), only 8 out of 35 genes in cluster #2 are 
reportedly expressed by or act on bone marrow derived cells (HPSE, CD24, HSPA4, 
JUNB, ZFP36, STAT3, VDAC1, and CCL20). The other genes in cluster #2 regulate 
keratinocyte proliferation, differentiation, and maturation or oxygen radical formation 
and quenching. This is an expected result since non-response to drug therapy is defined 
as continued keratinocyte hyperplasia and parakeratosis. Of the 8 “non-keratinocyte” 
genes differentially expressed by non-responders and responders, 4 promote leukocyte 
chemotaxis Heparinase (HPSE), CD24, JUNB, and CCL20), heat shock 70kDa protein 4 
(HSPA4) increases TLR4 expression on monocytes promoting an innate immune 
response, STAT3 promotes Th17 polarization, voltage-dependent anion channel 1 
(VDAC1) is also involved in T cell polarization, and zinc finger protein 36 (AFP36) 
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targets TNF for proteosome degradation. In summary, responders have decreased 
keratinocyte proliferation, leukocyte migration, Th17 polarization, and TNF negative 
feedback gene expression compared to non-responders.   
One possible explanation for non-response to etanercept treatment is that TNF 
was not completely inhibited by the drug.  To ascertain the level of TNF inhibition in 
non-responders we compared non-responder (n=4) and responder (n=16) expression of 
TNF early response genes IL-1β, IL-8, and iNOS (Figure 35E).  Although early gene 
downregulation is not statistically significant due to lack of sufficient power, these genes 
are downmodulated by week 1.  In contrast, other TNF modulated genes including p40 
and CCL3 are not downmodulated in non-responders, and IL-20 is not downregulated as 
rapidly (Figure 35F).  A summary of our proposed DC / T cell / keratinocyte interaction 
is presented in Figure 36.
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Figure 35. Differences between patients who responded to etanercept treatment and 
those who did not. Consensus Clustering on genes differentially modulated in etanercept 
non-responders and responders produced a delta curve (A) and Consensus Matrix (B) that 
identify 7 clusters, 4 of which had more than 4 genes (C). Corresponding heat map for 
cluster #2 (D).  RT-PCR on TNF early response genes in non-responders vs. responders 
(E), and downstream TNF-mediated genes (F). 
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Figure 36. Proposed role of Th17 and Th1 T cells in psoriasis pathogenesis.  TNF 
stimulates CD11c+ inflammatory DCs to produce IL-23 and IL-20.  DC activation and 
production of IL-23 supports Th17 survival and proliferation, and induces production of 
IL-17 and IL-22.  DC and Th17 products activate keratinocytes, promoting release of 
innate inflammatory molecules such as β-defensin, S100A7, and IL-8. Concurrently, Th1 
cells producing IFNγ activate keratinocytes to upregulate MHC-II molecules (HLA-DR) 
and integrins (ICAM), and release cytokines including MIG and IP-10.  Th1 and Th17 
cells may suppress each other’s development, but IFNγ can also act synergistically with 
IL-17 to increase ICAM expression and IL-8 release from keratinocytes. In psoriasis, 
etanercept may proximally inhibit this IL-23/IL-17 pathway to normalize keratinocyte 
proliferation and leukocyte infiltration. 
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Discussion 
Tumor Necrosis Factor (TNF) was initially identified in 1976 as the soluble, LPS-
dependent serum factor that killed murine fibrosarcoma cells but not normal fibroblasts 
(Green et al., 1976).  TNF was later identified as a macrophage-derived product that 
rapidly induced expression of IL-1, IL-6, and IL-8, leading to recruitment of innate 
inflammatory leukocytes within hours of the infectious insult (Clark et al., 1981; 
Hoffman, 1986).  This cytokine sequence, which might be termed the “sepsis cascade 
model,” has largely dominated thinking about the function of TNF in chronic 
inflammatory diseases.  Indeed, the initial rationale for testing TNF antagonists in 
rheumatoid arthritis was based on demonstrated increases in all sepsis cascade cytokines 
in synovial fluid of affected joints, as well as abundant neutrophils producing collagen-
destroying matrix metalloproteases (van Meurs et al., 1999).  Extension of these findings 
led to clinical trials of TNF antagonists in Inflammatory Bowel Disease and Psoriasis 
with subsequent therapeutic success and FDA approval.  Consequently, there has been a 
strong temptation to link pathogenesis of human inflammatory diseases, and especially 
those successfully treated with TNF antagonists such as psoriasis and rheumatoid 
arthritis, to direct effects of sepsis cascade cytokines on innate immunity.  However, 
despite the success of TNF blocking agents, psoriasis vulgaris clearly has some elements 
of pathogenesis that are not well explained by sepsis cascade cytokines and neutrophil 
activation.  First, there is clearly a strong T cell component in psoriasis, including 
multiple reports of T cell clonality, and there is considerable clinical benefit provided by 
T cell targeted therapeutics (Chang et al., 1997; Diluvio et al., 2006; Gottlieb et al., 1995; 
Prinz et al., 1994; Weinshenker et al., 1989).  Second, psoriasis has been induced in 
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several transplanted skin models without apparent involvement of neutrophils in 
converted grafts (Nestle and Nickoloff, 2005).  Third, recent success in treating psoriasis 
with antibodies to the p40 cytokine subunit shared between IL-12 and IL-23 implies a 
central role for Th1 and/or Th17 T cells  in the pathogenesis of this disease (Gottlieb et 
al., 2007; Krueger et al., 2007; McKenzie et al., 2006; Toichi et al., 2006; Yen et al., 
2006).  How then is TNF linked to pathogenic actions of T cells in psoriasis? 
 
 We believe that a critical link between TNF and the adaptive immune system 
occurs through a group of myeloid dendritic cells (DCs) termed TIP-DCs (TNF- and 
iNOS-producing DCs) (Lowes et al., 2005a; Serbina et al., 2003; Tam and Wick, 2004).  
In many cases, TIP-DCs are the most abundant type of leukocyte in psoriatic skin lesions 
and these cells have the ability to make key “downstream” cytokines such as IL-20 and 
IL-23 that affect other cell types in psoriasis lesions (Lowes et al., 2005a; Wang et al., 
2006).   For example, IL-20 has direct trophic effects on epidermal keratinocytes, where 
it serves as an inducer of NFkB and directly modulates several cellular/molecular features 
of psoriasis in model systems (Sa et al., 2007).  IL-23 is now viewed as an essential 
survival cytokine for Th17 T cells which are major pathogenic effector cells in psoriasis 
(Annunziato et al., 2007; McKenzie et al., 2006; Vanden Eijnden et al., 2005).  TIP-DCs 
are not only characterized by expressing large amounts of TNF cytokine, but also have 
high levels of TNF receptors, reflecting TNF’s ability to positively autoregulate TIP-DCs 
(Gottlieb et al., 2005).  TNF effects on DCs include DC maturation, stimulation of IL-23 
or IL-12 synthesis, increased antigen presenting capacity, and effects on secondary 
lymphoid tissue organization (Ware, 2005; Zaba et al., 2007b).  TNF induction of DC-
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dependent IL-23 production and downstream Th17 T cell activation provides a plausible 
TNF mediated link between the innate and adaptive immune system. 
  In prior work, we have established that TNF blockade with etancercept rapidly 
represses synthesis of several key TIP-DC cytokines, including TNF, IL-20, and IL-23, 
rapidly attenuates Th17 T cell products IL-17 and IL-22, and more slowly attenuates Th1 
IFNγ synthesis (Zaba et al., 2007a).  Targeted gene analysis using RT-PCR did not, 
however, provide a “global” view of qualitative/quantitative and temporal relationships 
of genes modulated by etanercept.  We believe the present results use gene array analysis 
to help clarify several elements in the inflammatory cascade that links TNF to adaptive 
immune responses in psoriasis.  First, while the sepsis cascade is self-amplifying and 
reaches completion within hours of the initial stimulus, the resolution of psoriasis might 
be viewed as the opposite process in which removal of a key stimulus “de-amplifies” 
progressive waves of gene transcription over a period of several weeks.  By studying the 
response at multiple time points after etanercept is administered, we have identified a 
cluster of genes downmodulated “early” and 3 other sets of progressive reductions in 
gene transcripts.   Second, the majority of genes downmodulated early were myeloid 
derived, suggesting that these cells are the primary target of TNF inhibitors.  Third, we 
demonstrate a functional link between IL-23p40 inhibition and decreased Th17 T cell 
polarization in a mixed leukocyte reaction, completing the journey from innate to 
adaptive immunity. 
This data has also given us the first view of global gene transcripts modulated by 
TNF, IL-17, or interferon-gamma in epidermal keratinocytes, and how these cytokine 
pathways are modulated by TNF neutralization.  Genes most significantly and rapidly 
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downmodulated following TNF inhibition were genes regulated by both TNF and IL-17, 
suggesting cytokine synergy or redundancy, a theory supported by known common 
regulation of NFkB (Awane et al., 1999; Qian et al., 2007). 
  Lastly, this study may inform on possible mechanisms for TNF-mediated 
extracutaneous manifestations in psoriasis vulgaris, such as arthritis and cardiovascular 
disease (CVD).  TNF inhibitors are frequently used as first-line drugs for psoriatic 
arthritis patients because of rapid joint disease resolution.  TNF is a known inducer of 
osteoclastogenesis and pathologic bone reabsorption in TNF-mediated autoimmune 
diseases through induction of AP-1, a dimeric complex containing FOS proteins (c-Fos, 
FOSB, FOSL1/Fra-1, Fra-2), Jun and ATF proteins (Asagiri and Takayanagi, 2007; 
Karin et al., 1997; Lam et al., 2000; Romas et al., 2002).  AP-1 potentiates RANKL on 
myeloid lineage cells, initiating differentiation into osteoclasts (Lam et al., 2000).  
Although murine models have been used to establish these mechanisms, our in vivo 
human model of TNF inhibition shows rapid downregulation of FOSB and FOSL1/Fra-1 
which may translate into decreased osteoclast mediated joint destruction.  Another 
rapidly downregulated gene, endothelial lipase (EL/LIPG), may explain known 
dyslipidemia associated with psoriasis.  TNF is an inducer of LIPG which cleaves 
triglycerides off of HDL and decreases plasma HDL concentrations  (Kempe et al., 
2005), and increases monocyte adhesion (Kojma et al., 2004).  At physiological levels, 
HDL protects against cardiovascular disease by reverse cholesterol transport (RCT), 
acting as a sink for cholesterol that could otherwise be deposited in macrophages in 
athlerosclerotic plaques (Popa et al., 2007).  Our data suggest a potential mechanism for 
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TNF causing low HDL in psoriasis patients, and that etancercept my reverse this 
pathway. 
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Our work has re-classified dermal dendritic cells in normal skin and inflamed 
psoriatic skin.  Until recently, normal and psoriatic dermal DCs were defined by FXIIIA 
expression, which we have shown to be a macrophage marker (Zaba et al., 2007b).  The 
immunohistochemical distinction between dermal DC and dermal macrophages is 
medically important as evidenced by recent discovery of FXIIIA+ cells mediating 
nephrogenic systemic fibrosis (NSF) in dialysis patients who have received gadolinium 
contrast (Kucher et al., 2005; Parsons et al., 2007).  NSF is characterized by fibrosis of 
the dermis and subcutaneous septae as well as fibrosis of organs, including the heart, 
liver, lungs and muscle.  Biopsy of lesional skin reveals increased CD68+FXIIIA+ cells 
containing gadolinium particles.  In the literature, these cells have been described as 
either dendritic cells, dermal dendrocytes, or fibroblasts, but as in our tattoo model, we 
suggest that the gadolinium particles are collected inside macrophages.  Accurately 
defining these FXIIIA+ cells as inflammatory macrophages and not antigen-presenting 
dendritic cells may have consequences on therapeutic targets for NSF treatment. 
 
In normal skin, we suggest that mature, immunostimulatory BDCA-1+ cells are 
the major resident dermal dendritic cell population.  Other groups have suggested a 
different classification system in normal skin with two non-overlapping subsets of 
immunostimulatory CD1ahi and non-immunostimulatory CD14+ cells (Angel et al., 2006; 
Angel et al., 2007).  The CD1a+ subset described by Angel et al. is also BDCA-1+, and 
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therefore corresponds to our definition of  BDCA-1+ resident dermal DCs.  In our hands 
using the “gold standard” immunohistochemistry and immunofluorescence for in situ 
characterization of dermal cells, we did not find many CD14+ cells.  Therefore, we 
believe that this subset of CD14+ cells are blood monocytes contaminating the 
preparation.   
 
Prior work on psoriatic dermal DCs defined them as FXIIIA+ immunostimulatory 
cells (Nestle et al., 1994).  FXIIIA is upregulated on all dermal dendritic cell populations 
during culture and emigration (unpublished data), and therefore the Nestle et al. model 
does not contrast with our own.  Functional studies showed that both BDCA-1+ and 
BDCA-1- myeloid DC psoriatic dermal emigres are equally immunostimulatory and 
TH17 polarizing.  This result is somewhat suprising considering that in situ double lable 
immunofluorescence clearly shows that all CD205+DC-LAMP+ cells are BDCA-1+, 
suggesting that BDCA-1+ cells should have greater antigen presenting capacity than 
BDCA-1- cells.  This discrepancy may be explained by BDCA-1- cells maturing and 
gaining immunostimulatory capacity during emigration from the dermis.  To support this 
theory, no CD11c+BDCA-1- cells are DC-LAMP+ by in situ immunofluorescence, but 
FACS on CD11c+BDCA-1- emigres shows 35% positivity for DC-LAMP.  We are also 
aware that defining a cell subset using a negative marker (aka BDCA-1-) is not ideal, and 
ongoing work will focus on establishing antigens that are uniquely expressed on the 
inflammatory BDCA-1- dermal DC population. 
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Double label immunofluorescence showed that many CD11c+ dermal cells 
produced TNF, and are thus likely targets of TNF neutralization therapies.  In a clinical 
trial using the TNF-blocking drug etanercept, RT-PCR and gene array analysis showed 
an expected rapid downmodulation of myeloid genes.  We also found that TH17 T cell 
gene products were rapidly downmodulated while Th1 T cell gene products were 
downregulated late in disease resolution.  Previous clinical trials using gene array to 
probe a drug’s mechanism of action include a cyclosporine (CSA) trial with the earliest 
treatment timepoint at 2 weeks (Haider et al., 2008).  Unlike etanercept which resulted in 
early and late gene modulation, CSA treated patients were globally immune suppressed 
by week 2.   
 
While some of the genes downmodulated early by TNF inhibition are known TNF 
early genes, many have not been previously reported.  Included in this early TNF-
dependent gene list are lipid metabolism and osteoclastogenesis genes that may inform 
pathways of extracutaneous manifestations of psoriasis. 
 
 Although this thesis describes DC subsets and functions in psoriasis vulgaris, 
these principals may be applied to other inflammatory conditions.  Non-MHC psoriasis 
susceptibility loci overlap with other inflammatory diseases such as atopic dermatitis 
(AD) (Cookson et al., 2001) and inflammatory bowel disease (IBD) (Lee et al., 2000), 
suggesting that these diseases may have overlapping inflammatory pathways.  Future 
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